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1. INTRODUCTION 
1.1 Cascade of leukocyte migration in the pathogenesis of inflammation 
Inflammation is the basic mechanism essential for tissue repair after an injury and consists of a 
cascade of cellular and microvascular reactions that serve to remove damaged and generate new 
tissue. Characterized by the classic clinical signs of inflammation - swelling, redness, pain, heat, 
and loss of function, the acute inflammation cascade includes increased permeability in 
microvessels, attachment of circulating cells to the vessels in the vicinity of the injury site, 
migration of several immune cell types, cell apoptosis, and growth of new tissue and blood vessels. 
Already at the end of XIXth century, Metchnikov laid the basic principles of inflammation by 
realizing that leukocytes escape from the blood vessels and then take up and digest bacteria that get 
into the body (1). In the next 100 years, his theory was extended and consolidated by discovering 
the molecular mechanisms underlying leukocyte activation, recruitment from the circulation, and 
trafficking toward the site of inflammation or injury. Recruitment and migration of leukocytes 
from the bloodstream to the site of injury or infection is a fundamental event in the inflammatory 
response, resulting in tissue dysfunction and damage (2), (3). Specific tissue infiltration by distinct 
leukocyte subpopulations indicates their critical function in the pathogenesis of inflammatory 
disease (4). 
Leukocyte recruitment in the microvasculature involves a multistep cascade of interactions of 
adhesion receptors between leukocytes and endothelial cells (5). Leukocyte rolling, adhesion and 
transmigration were described already in the nineteenth century. In the past decade, new insights 
have been gained into the mechanisms underlying integrin activation (6), into the post-adhesion 
events strengthen leukocyte attachment to the endothelium, and into the molecules that are 
involved in leukocyte transendothelial migration (7), (8). Therefore, the original three-step version 
of the leukocyte adhesion cascade has been expanded and now includes slow rolling, adhesion 
strengthening, intraluminal crawling, transendothelial migration, migration through the basement 
membrane, and interstitial migration (8) (Fig. 1). Initial tethering and rolling are mediated by P-,  
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E- and L-selectins (9), which interact with P-selectin glycoprotein ligand 1 (PSGL1) and other 
ligands (10), (11). Recent works suggest that not only selectins but also integrins such as 
lymphocyte function-associated antigen-1 (LFA-1) and macrophage receptor-1 (MAC-1) support 
leukocyte rolling (12), (13). Rolling brings the leukocyte into proximity with endothelial cells, 
where it can be activated by luminal surface-bound chemokines or lipid chemoattractants (for 
example, platelet activating factor – PAF) (14). Ligation of specific G-protein coupled receptors 
(GPCRs) by chemokines leads to rapid integrin activation via “inside-out” signaling that causes 
leukocyte arrest under shear stress conditions (8). In contrast, an “outside-in” signaling, which is 
downstream of endothelial ligand (intercellular adhesion molecule-1 - ICAM-1, vascular cell 
adhesion molecule - VCAM-1) binding to activated integrins probably contributes to adhesion 
stabilization and cell motility. In addition to mediating adhesion, integrins generate intracellular 
signals that regulate various cellular functions (15), (16). In this context, ligand-induced integrin 
clustering and conformational changes contribute to “outside-in” signaling and the formation of 
“signalosomes” that activate recruitment of protein tyrosine kinases and the initiation of various 
signaling pathways, which facilitate strengthening of adherent leukocytes on the endothelium (17), 
(8). Subsequently, leukocytes crawl inside the blood vessels in a MAC-1- and ICAM-1-dependent 
manner, seeking the preferred sites of diapedesis (18) (Fig. 1). After crawling, leukocytes migrate 
to a nearby endothelial border and squeeze between the tightly opposed endothelial cells to the 
underlying basement membrane in a next process - transendothelial migration (also called 
diapedesis) (19), (20).  
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Fig. 1. Cascade of leukocyte recruitment (description in text).  
Two main routes of leukocyte transendothelial migration are described in the literature: i) the 
transcellular route, when leukocytes emigrate through the body of endothelial cells, and ii) the 
paracellular route, when leukocytes emigrate through junctions between adjacent endothelial cells 
(Fig. 2) (19), (8). The “transcellular pathway" is regulated by vesicles, which have specific 
receptors or enable the adhesiveness by unspecific absorption to the membrane (21), (22). A lot of 
studies suggest that an engagement of endothelial ICAM-1 in transcellular migration via binding to 
LFA-1 on leukocytes induces the formation of microvilli-like endothelial cell projections 
embracing the migrating leukocyte in a cup-like structure (23), (24). A similar docking structure 
enriched for ICAM-1 and VCAM-1 was described, when leukocytes were found to induce spike-
like endothelial projections partially embracing those (24). Interestingly, cytoplasmic proteins and 
cytoskeletal components, such as alpha-actin, vinculin, and Wiskott–Aldrich syndrome protein 
(WASP) were also detected in the docking structures (25), (23). Most of the recently published 
studies identify, however, the paracellular migration route as the main mechanism by which 
leukocytes emigrate from the intravascular compartment into the interstitium (23). The current 
literature defines several endothelial cell contact proteins, such as platelet endothelial cell adhesion 
Ley K et al, Nat Rev Immunol, 2007 (modified) 
?
?
Transmigrationigration
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molecule-1 (PECAM-1), members of the junctional adhesion molecule (JAM) family (JAM-A, 
JAM-B, and JAM-C), CD99, and ICAM-2, as important receptors during transendothelial 
leukocyte migration, although the detailed mechanisms by which they mediate this process are not 
yet fully understood (7), (8). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Alternative passageways of leukocyte migration across endothelium. A - Leukocyte 
paracellular migration, which is mediated by homophilic interactions with endothelial adhesion 
molecules, such as PECAM-1, members of the JAM family, and probably ESAM and CD99, 
whereas VE-cadherin redistributes to the endothelial cell surface. B - Transcellular route of 
leukocyte transendothelial migration, which seems to be triggered by the ICAM-1. C – Electron 
microscopy image demonstrating both routes of transendothelial migration.  
 
C
A
B
C
Engelhardt B et al, Eur J Immun, 2004 
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1.1.1 Adhesion molecules involved in  leukocyte transmigration . 
Endothelial cells are tightly connected through various proteins that regulate the organization of 
the junctional complex and govern transendothelial leukocyte migration (8). In the endothelium, 
junctional complexes comprise tight junctions, adherens junctions, and gap junctions (Fig. 3). Gap 
junctions are communication structures which allow the passage of small molecular weight solutes 
between neighboring cells. Tight junctions are situated at the apical, intravascular side and include 
claudins, occludins, JAM, and endothelial cell-selective adhesion molecule (ESAM). They provide 
a "barrier" and a "fence" within the membrane. Adherens junctions are presented by cadherins, 
such as vascular endothelial cadherin (VE-cadherin) and catenins (β-catenin, placoglobin, p120), 
and play an important role for endothelial cell growth, angiogenesis, and paracellular endothelial 
permeability. In addition, endothelial cells express other adhesive proteins which are concentrated 
at the intercellular clefts but not specifically confined to adherens or tight junctions, such as 
PECAM-1, ICAM-1 and -2, and CD99. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Endothelial cell-cell contacts (description in text). 
http://www.mpi-muenster.mpg.de
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PECAM-1 (CD31) is one of the widely studied adhesion molecules involved in leukocyte 
transmigration. It is a member of the immunoglobulin gene superfamily that is expressed on 
leukocytes, platelets, neutrophils, monocytes, and selected T cell subsets (26). On endothelial cells, 
PECAM-1 is concentrated at intercellular junctions. Studies with neutralizing antibodies have 
indicated a role of PECAM-1 in leukocyte transmigration without any effect on adherence (27). It 
is well known that this adhesion molecule organizes endothelial cell-cell contact via homophilic 
interactions and binds to ligands on migrating leukocytes via heterophilic interactions. Disruption 
of PECAM-1-PECAM-1 homophilic interactions allows leukocytes to emigrate through the 
endothelial barrier (28), (29). Moreover, the homophilic interactions of PECAM-1 upregulate α6-
integrins as well as neutrophil elastase on transmigrating leukocytes that enables further neutrophil 
trafficking through the basement membrane (30), (31).  
JAMs are a family of glycoproteins characterized by two immunoglobulin folds (Vh- and C2-type) 
in the extracellular domain (32), (33). JAM proteins are localized in the intercellular junctions of 
polarized endothelial and epithelial cells but can also be expressed on circulating leukocytes and 
platelets (34). Blocking antibodies against JAM or JAM-deficiency decrease neutrophil or 
monocyte extravasation during meningitis and peritonitis as well as in inflammation models in 
skin, cremaster muscle, heart, and liver (35), (36). The mechanism of action of JAM-A in 
promoting leukocyte extravasation is not completely clarified because endothelial JAM-A may 
direct the movement of leukocytes through cell-cell junctions by either homophilic interactions 
with JAM-A expressed on the leukocyte membrane or by heterophilic interactions with endothelial 
JAM-A via binding to LFA-1 on leukocytes. Recent works showed that JAM-A is also required for 
neutrophil directional motility to the site of inflammation via integrin dynamic activation/inac-
tivation and cytoskeleton reorganization (37). In addition, also other members of the JAM family, 
such as JAM-B and JAM-C, are discussed to be involved in leukocyte adhesion, transmigration, 
and interactions between different cell subsets during inflammation (38). 
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VE-cadherin is an adhesion molecule that plays a role for the maintenance of interendothelial cell 
contacts (39). This protein is expressed at adherens junctions and associates with the cytoplasmic 
catenins. Plakoglobin (γ-catenin) and β-catenin connect VE-cadherin via α-catenin to the actin 
cytoskeleton (40). It was found that antibodies against human VE-cadherin dissociate the contacts 
of endothelial cells in culture (41). As shown in cultured cells as well as in vascular tissues, VE-
cadherin-containing adherent junctions during leukocyte diapedesis were relocated aside, not 
opened or disrupted and then moved back to their original positions when the leukocyte 
transmigration process was completed (42). 
ICAM-1 and ICAM-2 are members of the immunoglobulin superfamily of adhesion molecules 
composed of 2 N-terminal Ig domains with 35% homology, a transmembrane domain, and a short 
cytoplasmic tail of 27 amino acids (43). ICAM-1 is constitutively expressed on endothelial cells, 
platelets, and most leukocytes (43), (44). In contrast to ICAM-1, ICAM-2 appears to be 
concentrated at endothelial cell junctions (43). Both ICAMs represent endothelial ligands for the 
leukocyte β-2 integrin LFA-1 and have been shown to participate in the docking of leukocytes to 
the endothelium (24), (44). The role of ICAM-1 for leukocyte diapedesis was demonstrated in 
various in vitro studies with T cells (45) and monocytes in vivo (44), (46), (47). Several studies 
suggested a role of ICAM-2 for transmigration of all leukocyte subsets through stimulated and 
unstimulated HUVECs (45; 48). 
VCAM-1 is an adhesion molecule that is not constitutively expressed on endothelial cells but is 
upregulated by chemokines (49). It has been found that this molecule interacts with monocytes and 
lymphocytes and participates in leukocyte transmigration during the inflammatory response (7). A 
study in LFA-1-deficient mice revealed that VCAM-1 might play also a role in lymphocyte 
homing into primary lymphatic organs (50). Since VCAM-1 has not been identified at endothelial 
cell-cell contacts, it appears that this molecule exclusively mediates the attachment of leukocytes 
to the endothelium (7).  
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In addition to these relatively well investigated adhesion molecules, three recently discovered 
members of cell-contact proteins, ESAM, CD99, and CD99L2, are suggested to play an important 
role during leukocyte transendothelial migration. ESAM is an adhesion molecule that is 
specifically expressed at endothelial tight junctions and on platelets (51). ESAM is related to the 
JAM family, but differs considerably in structure, cytosolic binding partners (52), and tissue 
distribution (51). In contrast to the JAMs, expression of ESAM is strictly limited to endothelial 
cells and platelets and can not be found on leukocytes or epithelia (51). On platelets, ESAM is only 
expressed upon activation, whereas on endothelial cells it is strictly bound to tight junctions as 
demonstrated by immunogold labeling (53). Since ESAM is localized at endothelial tight junctions 
and has been shown to play a role in tumor angiogenesis (54), it might be also involved in 
leukocyte migration during the acute or chronic inflammatory response. However, the role of 
ESAM for leukocyte migration has not yet been analyzed. 
CD99 is a small (about 100 amino acids, 32 kD) membrane protein with a highly O-glycosylated 
extracellular part that is expressed on the surfaces of most leukocytes and is concentrated at the 
borders between confluent endothelial cells (55). It has been shown in vitro that CD99 plays a role 
in transmigration of human monocytes through the monolayer of human endothelial cells (55). In 
addition, antibodies against mouse CD99 inhibited the recruitment of lymphocytes in inflamed 
skin (56). Using HUVEC monolayers as a model of inflammation in vitro, Lou et al. found that 
antibodies against CD99 blocked over 80% of human neutrophil transmigration (57). It has been 
also shown that blocking of either the neutrophil or the endothelial CD99 led to quantitatively 
equivalent reduction of leukocyte extravasation (57). This fact suggests that an interaction between 
CD99 on the neutrophil and CD99 on the endothelial cell might occur to allow neutrophil 
diapedesis. In addition, blockade of both CD99 and PECAM-1 resulted in additive effects on 
monocyte migration in vitro, assuming that the two molecules work at distinct steps (57). 
However, the question of whether CD99 is involved in transendothelial migration in vivo has been 
not answered, so far. 
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CD99L2 represents a protein of unknown function with moderate sequence homology to CD99 
which is expressed on leukocytes and endothelial cells (58), (59). In tissues, this molecule is 
widely distributed with prominent expression on neuronal cells, choroid plexus, Sertoli cells, and 
granulosa and theca cells of the ovary (58). Although no studies have been performed that would 
attribute any function to CD99, it was tentatively named CD99 antigen like-2 (CD99L2) (59). 
Despite the structural homology to CD99, there are no data in the literature demonstrating a role of 
this receptor for leukocyte migration.  
 
1.2 Leukocyte interstitial migration 
After penetration of the endothelial barrier, leukocytes move in the interstitium to the site of injury. 
Leukocyte interstitial migration is suggested to be of a critical importance not only for tissue 
injury, but also for reparative events (60), (61), (62).  
Emigrated  immune cells moving within the interstitium are suggested to accomplish leukocyte 
chemotaxis – directed migration along gradients of chemotactic agents toward their destinations 
(63), (64), (65). Leukocyte chemotaxis is dependent on the ability of migrating cells to sense 
gradients of chemoattractants, serving as a “driving force” for immune cells (65), (66), (67). 
Several signaling pathways have been proposed to be involved in this gradient-amplification 
process, the most predominant being the phosphatidylinositol-3 kinase (PI3K) pathway (68). 
Thereby leukocytes use an „internal compass“ for sensing the direction of chemotactic gradients, 
and undergo polarization characterized by the formation of lamellipodia at the leading edge of the 
cell and an uropod at the trailing edge (69), (70). Chemokines are released by mast cells, smooth 
muscle cells, fibroblasts, myocytes, dendritic cells, and endothelial cells (67). The intercellular 
communication in the extracellular matrix (ECM) is mediated by glycosaminoglycans which 
interact with chemokines using low affinity interaction and, therefore, control the site and duration 
of soluble chemokine gradient (71), (72). In addition, glycosaminoglycans are suggested to be 
involved in transport, clearance, and degradation of chemokines (65). So called “interceptors” such 
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as DARC (Duffy antigen receptor for chemokines) and D6 are considered to transport chemokines 
and present them on the apical side of endothelium (13), (19). The effect of chemokines on 
leukocyte migration is accomplished by triggering GPCRs on the leukocyte surface. Recent studies 
have reported that leukocytes integrate signals from different combinations of cytokines that they 
encounter either simultaneously or sequentially within the ECM (71). The combinatorial effects of 
multiple chemokines and cytokines affect interstitially migrating leukocytes in a step-by-step 
manner, whereby cells react to chemotactic signals in their immediate vicinity by directional 
movement and remodeling of the ECM (67).  
Leukocytes moving within the interstitial tissue receive signals from neighboring cells as well as 
from the ECM, activate intracellular processes, release inflammatory mediators, and upregulate 
adhesion molecules and enzymes (73), (74). Although neutrophils display enhanced expression of 
β1-integrins upon transmigration, it remains a controversial discussion whether integrins are 
relevant for interstitial leukocyte migration (75), (76), (64), (77). In this context, leukocyte-
released proteolytic enzymes (proteases) such as heparase, elastase, and matrix metalloproteinases 
(MMP-2 and MMP-9) seem to play a critical role for leukocyte interstitial migration. They are 
required for the degradation of the components of the basement membrane as well as of the ECM 
and therefore allow leukocyte moving within interstitial microenvironment (78), (79).  
The next important issue is the cytoskeleton reorganization during leukocyte interstitial migration. 
In response to chemoattractants, leukocytes rapidly polarize in the direction of the signal, forming 
a pseudopod on the side of highest chemotactic concentration and an uropod or posterior domain 
on the opposite side of the cell; these structures become the leading and trailing edges of the 
chemotaxing cell, respectively (80). This process is mediated by leukocyte cytoskeletal dynamics. 
Cytoskeleton reorganization has been found to be regulated by JAM-A- and C (34), calcium-
dependent protease calpain (81), (52), LFA-1, CD11b/CD18 (Mac-1) and alpha-integrins (82) as 
well as by PI3Ks or the non-receptor tyrosine kinases, such as Syk or Btk (83), (84). Rho 
guanosine triphosphate proteases (Rho/GTPases) are also involved in regulation of cytoskeleton 
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reorganization during leukocyte chemotaxis (68), (73), (85). Being molecular switches that control 
a variety of signal transduction pathways in all eukaryotic cells, they are suggested to play a 
pivotal role in the regulation of cell polarity (86), microtubule dynamics (87), membrane transport 
pathways, and transcription factor activity in response to extracellular stimuli  
Although leukocyte interstitial migration is suggested to be of critical importance for the 
development of an inflammatory response and tissue repair, this process remains not fully 
understood. The vast majority of the studies on leukocyte directional migration were performed in 
vitro. However, there is a growing body of evidence suggesting that the mechanisms underlying 
leukocyte directional migration within the interstitium might differ between in vitro and in vivo 
settings (19), (65). Although two-dimensional (2D) substrates were preferentially used for in vitro 
studies on leukocyte chemotaxis, the mechanisms mediating this process seem to be rather 
different in 2D vs. 3D (three-dimensional) settings (77). 
Therefore, it has to be investigated which mechanisms mediate motility of leukocytes “primed” 
during transmigration in the interstitium in vivo in 3D-microenvironment and to which extent these 
mechanisms vary in dependency on the type of inflammation. Whilst 2-photon laser scanning 
microscopy enabled investigations on the dynamics of lymphocyte and dendritic cell migration in 
the lymph node (88), directional migration of leukocytes in inflamed “non-lymphatic” tissue is 
poorly understood. The studying of leukocyte interstitial migration in “non-lymphatic tissues” in 
vivo remains limited because of induction of diffuse inflammation with “chemotactic chaos” in the 
interstitium after usage of conventional routes of stimulation such as superfusion or local 
administration of chemoattractants (89), (90), (91).  
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2. OBJECTIVES 
The objectives of the present study were:  
1) To analyze the role of ESAM for leukocyte migration during IL-1β-induced acute local 
inflammation in the mouse cremaster muscle using in vivo microscopy (IVM). 
2) To characterize the role of CD99 and CD99L2 for leukocyte migration during IL-1β-induced 
acute local inflammation in the mouse cremaster muscle using IVM.  
3) To establish an in vivo approach enabling investigations of leukocyte directional interstitial 
migration in the natural 3D microenvironment.  
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3. MATERIAL AND METHODS 
All experiments were performed at the Institute for Surgical Research, Walter Brendel Centre of 
Experimental Medicine, Ludwig-Maximilians-Universität München, according to German 
legislation on the protection of animals and Government of Bavaria (reference number: 97-03). 
 
3.1 Animals 
Male C57BL/6 wild-type (Charles-River, Sulzfeld, Germany), ESAM-/-, and PECAM-1-/- mice 
with background C57BL/6 (generated and provided by the group of Prof. Dr. D. Vestweber, Max-
Planck-Institute of Molecular Biomedicine, Muenster, Germany) and weight from 20 to 25 g were 
used. The mice were held under control of day/night cycle in groups from 3 to 5 animals in 
Makrolon-cages and had free access to tap water and pellet food (ssniff Spezialdiäten, Soest, 
Germany).  
 
3.2 Reagents and inhibitors 
Recombinant mouse interleukin-1-beta (IL-1β), recombinant murine macrophage inflammatory 
protein-1 α (MIP-1α/Ccl3), and monocyte chemotactic protein-1 (MCP-1/Ccl2) were purchased 
from R&D Systems® (Wiesbaden-Nordenstadt, Germany). Phospholipid platelet-activating factor 
(PAF) and Rho kinase inhibitor Y27632 were purchased from Sigma Aldrich (Deisenhofen, 
Germany). 
 
3.3 Blocking antibodies  
The blocking antibodies used in our study were generated and provided by the group of Prof. Dr. 
D. Vestweber. Polyclonal rabbit antisera against mouse CD99L2 were generated against the 
CD99L2-Fc fusion protein. Antibodies against the IgG1-Fc part were removed from the serum by 
incubation with human IgG1-coupled to CNBr-activated Sepharose (Amersham Pharmacia 
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Biothech, Freiburg). Specific antibodies against CD99L2 were affinity-purified with CD99L2 
immobilized on CNBr-Sepharose. Affinity-purified polyclonal antibodies against mouse CD99 
were generated as described previously (92). F(ab')2-fragments were generated with immobilized 
pepsin on beads (Pierce, Rockford, IL) according to the manufacturer's protocol. Uncleaved IgG 
and Fc-fragments were removed using protein A Sepharose (GE Healthcare). Purity (< 0.3% intact 
IgG) and proper size of the F(ab')2-fragments were confirmed by sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE). Relative binding efficiency was tested by enzyme-
linked immunosorbent assay using CD99L2-Fc as antigen. No endotoxin was detectable. 
 
3.4 Model  
3.4.1 Anesthesia 
Animals were narcotized using intraperitoneal injection of Ketavet® (ketaminhydrochloride; 
100mg/kg) and Rompun® (xylazinhydrochroride; 10 mg/kg). This dose was sufficient to keep the 
mouse under anesthesia during 35-45 min. After initiation of anesthesia, the animals were fixed on 
a heating plate. The body temperature was controlled using a temperature sensor and kept 
constantly at 37°C. Additive intraperitoneal injections of ketamine (100 mg/kg) were performed 
during experiments lasting more than 1 hour. Short inhalation anesthesia (5 min) with isoflurane (2 
Vol. %, Forene®, Abbott GmbH, Wiesbaden, Germany) and N2O (FiO2 0.35) was used for the 
intrascrotal injection of inflammatory mediators.  
 
3.4.2 Catheterization of a. femoralis  
To administer fluorescent beads for the measurement of centerline blood flow velocity, the left 
femoral artery was catheterized in narcotized mice. Catheterization was performed on the 
microsurgical workstation with heated stage (37°) using a surgical microscope (Leica M651, 
Wetzlar, Germany). After incision of the skin in the middle of the hip, the fascia was removed and 
the arteria femoralis was dissected from vena femoralis and nervus femoralis (microscopic 
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magnification 25x). Then, the a. femoralis was ligated in the distal segment using silk ligature and 
clamped in the proximal segment using a vessel microclip (microscopic magnification 40x). After 
incision of the vessel, a propylene-catheter (0.28 ID/0.61 OD, Portex, UK) was inserted into the 
artery and then fixed using a silk ligature. 
 
3.4.3 Catheterization of v. jugularis interna 
Systemic application of antibodies was performed via a catheter placed in v. jugularis interna. 
After surgical preparation of the jugular vein from the surrounding tissue, a fine incision of the 
vessel was made using microscissors; the catheter was inserted into the vessel and fixed by two 
silk ligatures.  
 
3.4.4 Surgical preparation of cremaster muscle 
The surgical procedure was performed according to the technique described by Baez with slight 
modifications (93). The scrotum was moderately extended by means of an anchoring thread passed 
through the hind pole. After coagulation of blood vessels using careful electrocautery to stop any 
bleeding, an initial longitudinal incision of skin and fascia was made in the midline in a relatively 
avascular zone over the ventral aspect of scrotum. The incision was extended up to 5-8 mm above 
inguinal fold and to the distal end of the scrotum. Epididymis and testicle were detached from the 
cremaster muscle and placed into the abdominal cavity. Then, the cremasteric tissue was spread 
over the mirroring pedestal of a custom-made microscopic stage. Throughout the procedure as well 
as after surgical preparation during IVM, the muscle was superfused with warm (37°C) buffered 
saline. After surgical preparation, which usually required 10-20 minutes, the stage was transferred 
to the microscope. The temperature of the superfusion buffer was maintained at 37°C by a heating 
lamp and a measured by digital thermometer (TFN 1093, Ebro Electronic GmbH, Ingolstadt, 
Germany).  
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3.4.5 Near-infrared reflected light oblique transillumination (RLOT) microscopy  
The setup for IVM was centered on an Olympus BX50 upright microscope (Olympus Microscopy, 
Hamburg, Germany) equipped for stroboscopic fluorescence epi-illumination microscopy. Light 
from a 75-watt xenon source was narrowed to a near- monochromatic beam of a wavelength of 
700 nm by a galvanometric scanner (Polychrome II; TILL Photonics, Gräfelfing, Germany) and 
directed onto the specimen via an FITC filter equipped with dichroic and emission filters (DCLP 
500, LP515, Olympus Microscopy). Microscopic images were obtained with Olympus water 
immersion lenses (20x numerical aperture (NA) 0.5 and 40xNA 0.8) and recorded with an analog 
black and white charged-coupled device video camera (Cohu 4920, Cohu, San Diego, CA) and an 
analog video recorder (AG-7350-E, Panasonic, Tokyo, Japan). Oblique illumination was obtained 
by positioning a mirroring surface (reflector) directly below the specimen and tilting its angle 
relative to the horizontal plane. The reflector consisted of a round coverglass (thickness 0.19-0.22 
mm, diameter 11.8 mm), which was coated with aluminum vapor (Freichel, Kaufbeuren, 
Germany) and brought into direct contact with the overlying specimen.  
 
3.4.6 Microinjection of inflammatory mediators 
Microinjection was performed using a semiautomatic microinjector (FemtoJet®, Eppendorf, 
Hamburg, Germany) and a micromanipulator (InjectMan® NI 2, Eppendorf), consisting of a 
control board and a module unit with capillary holder (Fig. 4A). The injection parameters (tip 
pressure: 120 hPa; time of injection: 0.5 sec) were adjusted on the microinjector. The module unit 
comprises the motor unit for horizontal and vertical movement and serves for the installation of 
injection angle (Fig. 4A). As microcapillaries, borosilicate micropipettes with tip diameter <1 µm, 
connected to the capillary holder on the module unit were used. Through an exertion of joystick on 
the control board of the micromanipulator, the movements of the microcapillary were regulated 
under control of IVM (lens 4x, numeric aperture 0.12, Leitz, Wetzlar, Germany) (Fig.4A). 
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Single unbranched postcapillary venules with diameters between 20-35 µm and lengths >150 µm 
were selected for this study. Under control of IVM (objective magnification 4x), microinjection of 
chemoattractants was performed into the cremasteric tissue in the perivascular region 25-50 µm 
from the venule (Fig. 4B). A successful microinjection was verified by the observation of visible 
swelling of the interstitial tissue during injection. In control experiments with usage of rhodamine 
6G, the fluorescent dye could be clearly visualized in the tissue using fluorescence microscopy.  
Postcapillary venule as well as surrounding tissue were visualized at baseline conditions before 
stimulation as well as 60 min after microinjection under objective magnification 20x. Leukocyte 
recruitment and interstitial migration were analyzed after microinjection of either the CC 
chemokine MIP-1α (250 nM), the phospholipid PAF (100 nM), or saline (6 animals in each 
group). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. A - Microinjection system comprising the microinjector FemtoJet® and the 
micromanipulator InjectMan® NI 2, which consists of control board and module unit (modified 
illustration from the catalogue of “Eppendorf”). B - Schematic representation and intravital 
microscopic image demonstrating the technique of microinjection (objective magnification 4x).  
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3.4.7 Microhemodynamic parameters 
Centerline blood flow velocity was measured using microspheres (2µm; FluoSpheres; Invitrogen, 
Karlsruhe, Germany) administered intraarterially. Quantitative analysis of velocity was performed 
off-line using CAPImage® by measuring the distance between several images of one fluorescent 
bead under stroboscopic illumination. From measurement of the vessel diameters and centerline 
blood flow velocity, the Newtonian wall shear rate [s-1] was estimated as 8 x [Vb /d], where Vb is 
the mean blood flow velocity, d is the diameter of the vessel. Mean blood velocity, Vb, was 
approximated by multiplying the centerline blood velocity by 0.625. The interfacial shear rate is 
the slope of the velocity profile at the interface of the endothelial surface layer and the vessel 
lumen, and it was calculated as 4.9 x 8 x [Vb/d], where 4.9 is a mean empirical correction factor 
(94). 
 
3.4.8 Parameters of leukocyte recruitment   
Quantitative analysis of leukocyte-endothelial cell interactions was performed off-line using 
CAPImage®. Rolling leukocytes were defined as those moving slower than the associated blood 
flow and quantified during 30 seconds. Leukocyte rolling flux fraction was determined from video 
recordings by counting all visible cells passing through a plane perpendicular to the vessel axis and 
dividing this number by the total leukocyte flux through the vessel, which can be estimated by the 
product of the systemic leukocyte count, mean blood flow velocity, and estimated vessel cross-
sectional area. Firmly adherent cells were determined as those resting in the associated blood flow 
for more than 30 sec and related to the luminal surface per 100 µm vessel length. Emigrated cells 
were counted in regions of interests (ROIs) reaching out 75 µm to each side of a vessel over a 
distance of 100 µm vessel length and are presented per 104 µm2 tissue area.  
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3.4.9 Single cell tracking of emigrated leukocytes 
Intravital microscopic video recordings were transferred into a computer system using a frame 
grabber. Digital video sequences were analyzed using the imaging software “Simple PCI” 
(Hamamatsu Corporation/Compix Inc., Cranberry Twp, PA). On each side of analyzed vessel, at 
least 15 emigrated leukocytes were identified (Fig. 5A) within ROIs and tracked in the 
perivascular space within a time period of 5 min. Parameters of leukocyte motility, such as 
migration velocity (curve-line and straight-line) and migration distance (curve-line and straight-
line) were automatically calculated by the software. Curve-line migration distance is presented as a 
line connecting the position of migrating leukocyte at each time point (Fig. 5B, red line). Straight-
line distance represents the shortest line connecting the start and end point of the leukocyte 
migration track (Fig. 5B, black line). Velocity is the speed along the curve-line distance or 
straight-line distance, respectively.  
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Fig. 5. Analysis of motility of interstitially migrating leukocytes. A – A representative RLOT image 
showing interstitially migrating leukocytes in a perivascular region of the inflamed cremasteric 
tissue. B - Semiautomatic tracking of single leukocytes using the imaging software; the red line 
represents the curve-line migration distance from start point “S” to the end point “E”, whereas 
the black line shows the straight-line migration distance from the start point “S” to the end point 
“E”; the average migration distance is demonstrated as a blue line. 
 
 
 
3.4.10 Morphological changes and polarization in interstitially migrating leukocytes  
In separate experiments, morphological changes in interstitially migrating leukocytes were 
evaluated using RLOT microscopy under higher magnification (objective magnification 50x). 
Randomly chosen single leukocytes were visualized and recorded in ROIs for 5 min at 60 min 
after chemotactic stimulation performed either by microinjection or intrascrotal injection. 
Polarization of interstitially migrating leukocytes was analyzed in digitalized intravital 
microscopic images. The major axis and the minor axis of single interstitially migrating leukocytes 
were measured. Polarization was determined off-line by measuring the eccentricity of the cell 
which is equal to the ratio of the major axis of the cell (longest straight line that can be drawn 
across the cell) and minor axis (longest straight line that can be drawn across the cell at 90° to the 
major axis) (68). Leukocytes with eccentricity of ≥1.2 were considered as polarized (68).  
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E
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3.4.11 Tissue distribution of applied fluorescent dye per time 
In an attempt to get information about the character of tissue distribution of injected mediators, 
microinjection of the fluorescent dye rhodamine 6G (130 pl, 0.05%, Sigma Aldrich) was 
performed in the cremaster muscle according to the above described technique in a separate set of 
experiments (n=7). The distribution of rhodamin 6G in the interstitium was analyzed in the areas 
of interests using in vivo fluorescence microscopy (excitation: 530 to 560 nm, emission: >580 nm, 
Olympus). Light from a 75-watt xenon source was narrowed to a near monochromatic beam by a 
digitally controlled galvanometric scanner (Polychrome II, TILL Photonics, Gräfelfing, Germany). 
Fluorescence emission was collected by a CCD camera (Sensicam, PCO, Kelheim, Germany) and 
subjected to digital image analysis (TILL Vision 4.0; TILL Photonics). Spatial dynamics of the 
fluorescence intensity were measured before and within 60 min after microinjection and expressed 
as mean gray value (95). Mean gray values of three regions of interests (ROIs) (100 x 75 µm) were 
analyzed on the vessel side of the postcapillary venule ipsilateral to the microinjection, on the 
contralateral side as well as in the interstitial tissue 350 µm from the site of microinjection 
(considered as background). 
 
3.4.12 Visualization of mitochondrial redistribution in interstitially migrating leukocytes  
Upon stimulation with chemoattractants, the redistribution of mitochondria was analyzed in single 
interstitially migrating leukocytes after intraarterial application of green-fluorescent mitochondrial 
stain MitoTracker® Green (200 nM, 150 µl, Invitrogen, Germany) immediately before surgical 
preparation of the muscle. MitoTracker® Green-labeled interstitially migrating leukocytes were 
visualized in perivenular regions 60 min after intrascrotal injection of PAF using the following 
technical devices: epifluorescent microscope, AxioTech-Vario 100 Microscope (Carl Zeiss, Jena, 
Germany; objective magnification 63x, N.A 1.0 water dipping), LED (Light Emitting Diode 
Colibri, Zeiss) light source for fluorescent illumination (470 nm) and near-infrared RLOT 
illumination (625 nm, filter cube 62 HE, Zeiss). IVM images were obtained with a digital 
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Highspeed-camera AxioCam Hsm (Zeiss), time-lapse recordings (4.5 min) were analyzed using the 
AxioVision 4 software (Zeiss).  
 
3.4.13 Imaging of the migratory behavior of leukocyte subsets 
Visualization and quantitative analysis of transendothelial and interstitial migration of neutrophils 
and Cx3CR1gfp/gfp-positive monocytes were made in Cx3CR1gfp/gfp mice 60-90 min after 
microinjection of MCP-1 (115 nM; n=1). The microinjection was performed at a distance of 25-50 
µm from the vessel. Cx3CR1gfp/gfp mice expressing green fluorescent protein (GFP) in blood 
monocytes were used. Interstitial migration of Cx3CR1gfp/gfp-positive cells (monocytes) and 
Cx3CR1gfp/gfp-negative cells (neutrophils) was visualized using the combination of RLOT and 
fluorescence microscopy (objective magnification 20x) and analyzed in perivenular ROI (100 x 75 
µm) on the vessel side ipsilateral to microinjection. Digital intravital microscopic video sequences 
were analyzed using Simple PCI software. Single cell tracking of extravasated Cx3CR1gfp/gfp-
negative neutrophils or Cx3CR1gfp/gfp-positive monocytes (n=5 in each group) was performed at 
60, 70, and 80 min after microinjection of MCP-1 for 5 min, respectively.  
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3.5 Experimental protocols and experimental groups 
3.5.1 Role of ESAM for IL-1β-induced leukocyte migration in vivo 
The effect of ESAM deficiency on leukocyte migration was analyzed in wild-type and ESAM-
deficient mice pretreated by intrascrotal injection of 50 ng of recombinant mouse IL-1β diluted in 
0.3 mL PBS (30), (96). The intravital microscopic measurements were performed 4 h after 
stimulation (Tab. 1; Fig. 6). To evaluate a role of ESAM during an earlier phase of IL-1β-induced 
inflammation, leukocyte migration was analyzed 2 h after intrascrotal injection of IL-1β in wild-
type and ESAM-/- mice (Tab. 1). Blood flow velocity and the systemic leukocyte count were 
measured at the end of each experiment (Fig. 6). The hemodynamic parameters as well as the 
parameters of leukocyte migration were analyzed as described above in 3.4.7 and 3.4.8. 
Tab. 1. Experimental groups assessed in the study of the role of ESAM for leukocyte migration in 
vivo. 
 
Stimulus Application of IL-1β Animals N 
IL-1β 4 h prior IVM  ESAM+/+ 7 
IL-1β 4 h prior IVM ESAM-/- 7 
IL-1β 2 h prior IVM   ESAM+/+ 3 
IL-1β 2 h prior IVM ESAM-/- 3 
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Fig. 6. Experimental protocol applied in the study of the role of ESAM for leukocyte migration in 
vivo. 
 
3.5.2 Role of CD99 and CD99L2 for IL-1β-induced leukocyte migration in vivo 
An acute inflammatory response in muscle tissue was achieved by intrascrotal injection of 
recombinant mouse IL-1β (50 ng). Mice were treated with either control IgG (50 µg), anti-CD99 
monoclonal antibody (50 µg), or anti-CD992L monoclonal antibody (50 µg) infused intravenously 
(Tab. 2; Fig. 8). The application of antibodies was performed immediately before intrascrotal 
injection of IL-1β (Fig. 8). To avoid unspecific activation of neutrophils via Fc-receptors, F(ab’)2-
fragments of anti-CD99 (75 µg), anti-CD99L2 (75 µg), and pre-immune control IgG (75 µg) were 
infused after IL-1β stimulation (Tab. 2). In additional groups, potential synergistic effects between 
CD99 and CD99L2 with PECAM-1 during leukocyte migration were analyzed in PECAM-1-/- 
mice treated with either control-IgG, anti-CD99, or anti-CD99L2 antibody (Tab. 2). In all groups, 
the parameters of leukocyte migration were assessed at 4 h after stimulation, whereas the 
hemodynamic parameters and the systemic leukocyte count were measured at the end of each 
experiment (Fig. 7). 
 
-240 min 0 min-30 min 10 min
IL-1β i.s.
Catheterization of a.femoralis. Surgical preparation of cremaster muscle. 
Intravital microscopic observation of leukocyte migration.
Measurement of blood flow velocity. 
Heart puncture and analysis of systemic leukocyte count.
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Tab. 2. Experimental groups assessed in the study of the role of CD99 and CD99L2 for leukocyte 
migration in vivo. 
 
Stimulus Animals Treatment N 
IL-1β wild-type IgG 6 
IL-1β wild-type anti-CD99  6 
IL-1β wild-type anti-CD99L2 6 
IL-1β PECAM-1-/- IgG 6 
IL-1β PECAM-1-/- anti-CD99  6 
IL-1β PECAM-1-/-  anti-CD99L2  6 
IL-1β wild-type IgG-F(ab’)2 6 
IL-1β wild-type anti-CD99-F(ab’)2 6 
IL-1β wild-type anti-CD99L2-(Fab’)2 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Experimental protocol applied in the study of the role of CD99 and CD99L2 for leukocyte 
migration in vivo.  
-240 min 0 min-30 min 10 min
IL-1β i.s.
Catheterization of a.femoralis. Surgical preparation of cremaster muscle. 
Intravital microscopic observation of leukocyte migration.
Measurement of blood flow velocity. 
Heart puncture and analysis of systemic leukocyte count.
Application of antibodies i.v.
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3.5.3 Imaging and quantitative analysis of leukocyte directional migration in vivo  
In a first set of experiments, to find an optimal protocol for microinjection and to assess the extent 
of local inflammation in dependency on the distance between the site of microinjection and the 
adjacent vessel, microinjections of MIP-1α were performed at three different distances from the 
venule: 25-50 µm, 75-100 µm, and 175-200 µm. The numbers of adherent and transmigrated 
leukocytes were calculated 60 min after microinjections in ROIs (100 x 50 µm) along the venule. 
Next, microinjection of rhodamine 6G (130 pl) was performed in the cremaster muscle according 
to the above described technique in order to investigate tissue distribution of injected mediators 
(n=7). The areas of interest (100x50 µm) were scanned using intravital fluorescence microscopy 
and fluorescence intensity was measured 1, 10, 30, 45, and 60 min after microinjection as 
described in 3.4.11. 
In order to investigate the character of leukocyte migration upon stimulation with different 
mediators, either MIP-1α (250 nM) or PAF (100 nM) were administered via microinjection in 
perivascular regions at the distance of 25-50 µm from a postcapillary venule (6 animals in each 
group) (Tab. 4). The animals undergoing microinjection of saline served as controls (n=6). The 
vessel and the surrounding tissue were visualized by near-infrared RLOT IVM during a time 
period of 5 min 60 min after microinjection (Fig 8). In order to compare the character of leukocyte 
migration after microinjection of inflammatory mediators with that induced by the conventional 
route of stimulation, intrascrotal injection of PAF (100 nM in 0.3 ml PBS) was performed in an 
additional experimental group at 60 min prior to IVM (see Tab. 4). 
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Tab. 4. Experimental groups assessed in the study of leukocyte migration after microinjection of 
chemoattractants in vivo. 
Stimulus Animals Application N 
saline  C57BL/6 microinjection           6 
MIP-1α  C57BL/6 microinjection 6 
 
PAF 
 
            C57BL/6 microinjection 6 
PAF   C57BL/6 intrascrotal injection 3 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Experimental protocol applied in the study of leukocyte migration after microinjection of 
chemoattractants in vivo. 
 
In addition, we analyzed the role of Rho kinase for motility of interstitially migrating leukocytes in 
vivo. Parameters of leukocyte motility were analyzed after inhibition of Rho kinase with a selective 
Catheterization of a.femoralis. Surgical preparation of cremaster muscle. 
Microinjection/intrascrotal injection of chemoattractant. .
Measurement of blood flow velocity. 
Heart puncture and analysis of systemic leukocyte count.
Intravital microscopic observation of leukocyte migration.
- 30 min 0 min 60 min
Single cell tracking of interstitially migrating leukocytes.
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inhibitor Y-27632 (50 µM) (87), (97)). Leukocyte migration was initiated by microinjection of 
MIP-1α, as described above (Tab. 5). Sixty min after microinjection of MIP-1α, the exteriorized 
cremaster muscle was superfused with Y-27632 for either 5 or 30 min (Tab. 5; Fig. 9). Intravital 
microscopic analysis was performed in two separate groups either 5 min or 30 min after 
superfusion of Y-27632. For both inhibitor-treated groups, corresponding time controls were 
performed with saline superfusion (Tab. 5; Fig. 9). 
Tab. 5. Experimental groups assessed in the study of the role of Rho kinase for motility of 
interstitially migrating leukocytes in vivo. 
 
Stimulus Treatment Observation time Animals Application N 
MIP-1α  - 60-65 min C57BL/6 microinjection           3 
MIP-1α Y27632 60-65 min C57BL/6 microinjection 3 
MIP-1α  - 90-95 min C57BL/6 microinjection 3 
MIP-1α  Y27632 90-95 min C57BL/6 microinjection 3 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Experimental protocol applied in the study of the role of Rho kinase for leukocyte 
interstitial migration in vivo. 
Catheterization of a.femoralis. Surgical preparation of cremaster muscle. 
Superfusion of Y27632. 
Heart puncture and analysis of systemic leukocyte count.
Intravital microscopic observation of leukocyte migration.
Microinjection of MIP-1α.
- 30 min 0 min 60 min
Single cell tracking of interstitially migrating leukocytes.
90 min
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Morphological changes and polarization of interstitially migrating leukocytes were evaluated using 
RLOT microscopy under a higher magnification (objective magnification 40x). Randomly chosen 
single leukocytes were visualized in ROIs i) 60 min after microinjection of PAF, ii) 60 min after 
intrascrotal injection of PAF, iii) and 60 min after microinjection of PAF followed by superfusion 
(30 min) with the Rho kinase inhibitor Y27632. 
To visualize the redistribution of mitochondria in single interstitially migrating leukocytes upon 
stimulation with a chemoattractant, green-fluorescent mitochondrial stain MitoTracker® Green was 
applied via the a. femoralis catheter before surgical preparation of the cremaster muscle. 
MitoTracker® Green-positive interstitially migrating leukocytes were visualized in perivenular 
regions 60 min after intrascrotal injection of PAF.  
In the last part of the study, we compared the migration patterns of neutrophils and monocytes 
upon microinjection of MCP-1. In these experiments, transgenic mice were used in which 
monocytes express green fluorescence protein (GFP). Intravital microscopic analysis was 
performed 60, 70, and 80 min after stimulation as described in Material and Methods. 
 
3.5.4 Statistical analysis 
Groups were compared with either ANOVA on ranks followed by Student-Newman-Keuls test 
(multigroup comparison) or t-test (two-group comparison) using SigmaStat statistic program 
(Jandel scientific, Erkrath, Germany). Mean values ± standard error of the mean (SEM) are given. 
Differences between experimental groups reaching p value <0.05 were considered significant. 
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4. RESULTS 
 
4.1 The role of ESAM for IL-1β-induced leukocyte migration in vivo 
4.1.1 Microhemodynamic parameters 
 In the first part of our study, we investigated the role of ESAM for regulation of leukocyte 
migration in vivo. Microhemodynamic parameters, such as diameter of the vessel, centerline blood 
velocity, wall shear rate did not significantly differ among experimental groups (Tab. 6). Systemic 
white blood cell counts (WBC) were also comparable between all experimental groups (Tab. 6). 
 
Tab. 6. Microhemodynamic parameters.  
Parameter 
IL-1ß – 4h 
ESAM+/+  
(n=7) 
IL-1ß – 4 h 
ESAM-/- 
(n=7) 
IL-1ß – 2h 
ESAM+/+  
(n=2) 
IL-1ß – 2h   
ESAM-/- 
(n=2) 
Vessel diameter (µm) 26.8 ± 0.9 26.4 ± 0.5 27.8 ± 3.9 28.1 ± 0.4 
WBC (106 cells x ml-1) 3.9 ± 0.5 3.1 ± 0.3 4.9 ± 0.2 4.6 ± 1.0 
Centerline blood velocity 
(µm/sec) 1.8 ± 0.1 1.8 ± 0.1 1.6 ± 0.1 1.8 ± 0.1 
Newtonian wall shear rate (8 
xVmean/ diameter) 339.1 ± 12.9 344.5 ± 9.4 475.0 ± 42.2 454.05 ± 28.9 
Interfacial wall shear rate (4.9 x 
8 xVmean/ diameter) 1661.6 ± 63.1 1687.9 ± 45.9 2327.5 ± 206.8 2224.8 ± 141.6 
 
mean ± SEM, * p<0.05. 
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4.1.2 Leukocyte migration parameters 
Four hours after intrascrotal injection of IL-1ß, leukocyte rolling flux fraction remained 
comparable between wild-type and ESAM-/- mice (16.9 ± 4.5% vs. 15.9 ± 1.3%, respectively; Fig. 
10A). Similarly, the number of adherent leukocytes in postcapillary venules did not differ between 
these two groups (13.1 ± 0.6 n/104µm2 vs. 13.0 ± 0.5 n/104µm2, respectively; Fig. 10B). In 
contrast, leukocyte transendothelial migration was reduced by about 50% in ESAM-/- mice (13.6 ± 
0.6 n/104µm2) as compared to wild-type mice (24.9 ± 1.1 n/104µm2; Fig. 10C). 
In an attempt to exclude that the effect observed at the level of leukocyte emigration was caused by 
differences in leukocyte rolling or adhesion at an earlier time point within the 4h period after 
stimulation, we assessed leukocyte migration 2h after the stimulation (Fig. 11). Leukocyte rolling 
flux fraction did not significantly differ between wild-type and ESAM-/- mice (16.2 ± 1.7% vs. 
16.2 ± 1.6%, respectively), and the results were comparable with the data obtained 4h after IL-1ß 
application. The levels of leukocyte adhesion, however, were here clearly lower in both groups as 
compared to those 4 hours after IL-1ß application (Fig. 10B and Fig. 11B) and remained similar 
between wild-type and ESAM-/- mice (7.6 ± 0.3 n/104µm2 vs. 7.6 ± 0.9 n/104µm2, respectively). 
The numbers of emigrated leukocyte were considerably lower as compared to those 4 hours after 
IL-1ß application (Fig. 10C and Fig. 11C) and they were reduced in ESAM-/- mice (5.2 ± 1.0 
n/104µm2) as compared to wild-type mice (7.1 ± 1.3 n/104µm2) (Fig. 11C). 
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Fig. 10. Leukocyte rolling flux fraction (A), adhesion (B), and transmigration (C) in 
postcapillary venules of wild-type and ESAM-/- mice 4 h after intrascrotal injection of IL-1ß; 
mean ± SEM,* p<0.05; n=7. 
A
B
C
%
*
n
/1
04
µm
2
n
/1
04
µm
2
ESAM+/+ ESAM-/-
0
10
20
30
40
50
ESAM+/+ ESAM-/-
1/
10
µm
0
5
10
15
20
0
5
10
15
20
25
30
wild-type         ESAM-/-
wild-type         ESAM-/-
wild-type         ESAM-/-
%
n
/1
04
µm
2
n
/1
04
µm
2
1/
10
µm
 
RESULTS   37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11. Leukocyte rolling flux fraction (A), adhesion (B), and transmigration (C) in 
postcapillary venules of wild-type and ESAM-/- mice 2 h after intrascrotal injection of IL-1ß; 
mean ± SEM; n=2. 
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4.2 The role of CD99 and CD99L2 for IL-1β-induced leukocyte migration in vivo 
In this part of the study, we analyzed the role of CD99 and CD99L2 for leukocyte migration in 
vivo. In addition, we answered the question whether blockade of CD99 or CD99L2 in combination 
with PECAM-1-defiency would have a synergistic inhibitory effect on leukocyte migration.  
 
4.2.1 Microhemodynamic parameters 
Microhemodynamic parameters, such as diameter of the vessel, centerline blood flow velocity, 
wall shear rate, and systemic leukocyte counts did not significantly differ between all experimental 
groups (Tab. 7A). As shown in Tab. 7B, microhemodynamic parameters and systemic leukocyte 
counts were comparable among mice treated with anti-F(ab’)2 preimmune IgG, anti-F(ab’)2-
CD99L2, or anti-F(ab’)2-CD99. The data were comparable with the findings obtained after 
application of intact antibodies (Tab. 7A-B).  
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Tab. 7A. Microhemodynamic parameters. 
Parameter 
 
wild-type 
IgG 
 
 
wild-type 
anti-
CD99L2 
 
wild-type 
anti-CD99 
 
 
PECAM-1/-                  
IgG 
 
 
PECAM-1/-     
anti- 
CD99L2 
PECAM-1/- 
anti-CD99 
Vessel 
diameter 
(µm) 
28.3 ± 0.6 27.0 ± 0.4 24.8 ± 0.8 26.4 ± 0.4 27.6 ± 1.1 26.6 ± 0.7 
Centerline 
blood flow 
velocity 
(mm x s-1) 
1.82 ± 0.04 1.75 ± 0.04 1.77 ± 0.03 1.78 ± 0.03 1.80 ± 0.03 1.73 ± 0.04 
Newtonian 
wall shear 
rate (s-1) 
319.0 ± 12.9 332.2 ± 8.8 366.3 ± 15.3 335.4 ± 9.0 348.6 ± 8.8 335.4 ± 9.1 
Interfacial 
wall shear 
rate (s-1) 
1563.1 ± 
63.2 
1627.7 ± 
43.1 
1794.8 ± 
74.9 
1643.4 ± 
44.1 
1708.1 ± 
43.1 
1643.4 ± 
44.6 
WBC (x 106 
cells x ml1) 5.6 ± 0.7 4.8 ± 0.6 3.9 ± 0.6 4.9 ± 0.8 3.7 ± 0.4 5.0 ± 0.5 
 
mean ± SEM,* p<0.05; n=6. 
 
Tab. 7B. Microhemodynamic parameters. 
Parameter 
wild-type 
anti-IgG- 
F(ab’)2 
 
wild-type 
anti- 
CD99L2F(ab’)2 
 
wild-type 
antiCD99- 
F(ab’)2 
 
 
 WBC ( x 106 cells x ml-1) 4.9 ± 0.6 4.8 ± 0.8 5.0 ± 0.85 
 
Vessel diameter (µm) 26.9 ± 0.8 26.6 ± 1.0 28.6 ± 0.6 
Centerline blood flow velocity 
(mm x s-1) 1.75 ± 0.04 1.73 ± 0.04 1.76 ± 0.01 
Newtonian wall shear rate (s-1) 335 ± 16.2 336 ± 13.7 318 ± 8.1 
Interfacial shear rate (s-1) 1641.5 ± 79.3 1646 ± 67.1 1558 ± 39.6 
 
mean ± SEM,* p<0.05; n=6.   
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4.2.2 Parameters of leukocyte migration 
 
4.2.2.1 Leukocyte rolling flux fraction 
 Leukocyte rolling flux fraction was determined in postcapillary venules upon application of IL-1β 
in either wild-type or PECAM-1-/-mice pretreated with control antibody (IgG), anti-CD99, or anti- 
CD99L2 antibody. As shown in the Fig. 12, no significant differences were detected between the 
experimental groups irrespective applied interventions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12. Leukocyte rolling flux fraction in postcapillary venules of wild-type and PECAM-1-/- mice 
4h after i.s. injection of IL-1ß and after i.v. application of either preimmune IgG, anti-CD99, or 
anti-CD99L2 antibodies; mean ± SEM,* p<0.05;  n=6. 
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As an additional control, leukocyte rolling flux fraction was measured in microvessels of wild-type 
mice and PECAM-1-/- mice treated with F(ab’)2-fragments of IgG, CD99 or CD99L2 antibodies 
(Fig. 13). Similarly to the results obtained with intact antibodies, the F(ab’)2-fragments did not 
affect IL-1β-induced leukocyte rolling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13. Leukocyte rolling flux fraction in postcapillary venules of wild-type mice 4h after i.s. 
injection of IL-1ß. The mice were treated with F(ab’)2-fragments of either preimmune IgG, anti-
CD99, or anti-CD99L2 antibodies; mean ± SEM,* p<0.05;  n=6. 
 
 
4.2.2.2 Leukocyte adhesion 
 In the group pretreated with control (preimmune) IgG, 11.1 ± 1.5 n/104µm2 adherent leukocytes 
were detected 4h after intrascrotal injection of IL-1ß (Fig. 14). Upon pretreatment with anti-CD99 
antibody or anti-CD99L2 antibody, the extent of IL-1ß-induced leukocyte adhesion remained not 
significantly different (12.5 ± 5.3 n/104µm2 and 11.3 ± 0.9 n/104µm2, respectively) as compared to 
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the group pretreated with control IgG. In PECAM-1-/- mice, leukocyte adhesion remained on the 
same level as observed in wild-type mice and was not significantly affected by the antibodies 
applied (Fig. 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14. Leukocyte adhesion in postcapillary venules of wild-type and PECAM-1-/- mice 4h after 
i.s. injection of IL-1ß with i.v. application of either preimmune IgG, anti-CD99, or anti-CD99L2 
antibodies; mean ± SEM,* p<0.05; n=6. 
 
 
In a separate set of experiments, leukocyte adhesion was assessed in wild-type mice treated with 
F(ab’)2-fragments of IgG, anti-CD99, or anti-CD99L2 antibodies. As demonstrated in Fig. 15, no  
significant differences were detected between experimental groups. 
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Fig. 15. Leukocyte adhesion in postcapillary venules of wild-type mice 4h after i.s. injection of IL-
1ß with i.v. application of F(ab’)2-fragments of either preimmune IgG, anti-CD99, or anti-
CD99L2 antibodies; mean ± SEM,* p<0.05; n=6. 
 
 
4.2.2.3 Leukocyte transmigration  
In wild-type mice pretreated with IgG, intrascrotal injection of IL-1β strongly induced 
transendothelial migration of leukocytes into the perivascular space (20.2 ± 0.6 n/104µm2) (Fig. 
16). In contrast, the number of emigrated leukocytes was significantly lower in mice received 
antibodies against CD99 and CD99L2 (9.8 ± 0.4 n/104µm2 and 10.4 ± 0.8 n/104µm2, respectively). 
In PECAM-1-/- mice pretreated with control IgG, leukocyte transmigration was significantly 
attenuated as compared to wild-type mice (Fig. 16). Moreover, leukocyte transmigration was 
reduced by about 50% in PECAM-1-/- mice received anti- CD99 or anti-CD99L2 antibodies as 
compared to PECAM-1-/- mice treated with IgG and by about 25% as compared to wild-type mice 
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treated with control IgG. The extent of leukocyte transmigration was comparable between wild-
type mice and PECAM-1-/- mice which received anti-CD99 or anti-CD99L2 antibodies (Fig.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16. Leukocyte transmigration in postcapillary venules of wild-type and PECAM-1-/- mice 4h 
after i.s. injection of IL-1ß with i.v. application of either preimmune IgG, anti-CD99 or anti-
CD99L2; mean ± SEM,* p<0.05 vs. preimmune IgG in C57BL/6 mice. #, $ p<0.05 vs. preimmune 
IgG in PECAM-1-/- mice; n=6. 
 
 
Additional experiments using (Fab)’2-fragments demonstrate that leukocyte transmigration in mice 
received anti-CD99-(Fab’)2 or anti-CD99L2-F(ab’)2 was significantly attenuated as compared to 
that in mice treated with IgG-(Fab’)2 fragments (Fig. 17). Noteworthy, the numbers of 
transmigrated leukocytes after administration of F(ab’)2-fragments of antibodies were comparable 
with those after application of their intact forms (Fig. 16 and Fig. 17). 
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Fig. 17. Leukocyte transmigration in postcapillary venules of wild-type mice 4h after i.s. injection 
of IL-1ß with i.v. application of F(ab’)2-fragments of either preimmune IgG, CD99, or anti-
CD99L2; mean ± SEM,* p<0.05 vs F(ab’)2-fragments of preimmune IgG; n=6. 
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4.3 Imaging and quantitative analysis of leukocyte directional interstitial migration in vivo 
  
4.3.1 Microhemodynamic parameters and systemic leukocyte counts  
To assure intergroup comparability, diameters of analyzed microvessels, centerline blood flow 
velocity, wall shear rate, and systemic leukocyte counts were measured. No significant differences 
were detected among experimental groups (Tab. 8).  
 
Tab. 8. Microhemodynamic parameters. 
 
Parameter Diameter 
(µm) 
Centerline 
blood flow 
velocity 
(mm/s) 
Newtonian 
shear rate 
(s-1) 
Interfacial 
shear rate 
(s-1) 
Systemic 
leukocyte 
counts 
(106cells/m) 
saline 30.4 ± 1.6 1.95 ± 0.1 318.5 ± 33.1 1560.6 ± 162.2 4.6 ± 1.9 
MIP-1α 29.9 ± 5.9 1.76 ± 0.2 302.0 ± 57.5 1479.8 ± 281.7 4.9 ± 2.0 
PAF 28.3 ± 2.6 1.92 ± 0.2 341.4 ± 31.8 1670.9 ± 155.8 4.6 ± 1.5 
PAF 
intrascrotal 
29.4 ±  2.0 1.79 ± 0.8 320.4 ± 20.1 1569.9 ± 98.5 4.2 ± 2.4 
 
mean ± SEM,* p<0.05; n=6. 
 
 
 
4.3.2. Determination of the optimal distance for microinjection of chemoattractants 
To find an optimal protocol for the perivenular microinjection of chemoattractants and to assess the 
extent of local inflammation in dependency on the distance of microinjection to the vessel, we first 
analyzed leukocyte adhesion and transmigration after microinjection of MIP-1α performed at three 
different distances from a venule: 25-50 µm, 75-100 µm, and 175-200 µm (Fig. 18A). Sixty 
minutes after microinjection of MIP-1α, the number of adherent and transmigrated leukocytes was 
analyzed in regions of interests (ROIs; 100 x75 µm). As a result, the highest number of adherent 
and transmigrated leukocytes was found when the microinjection was performed at a distance of 
25-50 µm, whereas the lowest numbers were found after microinjection at a distance of 175-200 
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µm (Fig. 18). Therefore, these data show that i) the distance of 25-50 µm from the postcapillary 
venule is optimal for microinjection of chemoattractants, since the inflammatory response is more 
stronger than after microinjections at the two longer distances analyzed. ii) microinjection of MIP-
1α induced an inflammatory response in an area of approximately 100 µm in diameter. 
Consequently, microinjection was performed at a distance of 25-50 µm from the postcapillary 
venule under investigation in all further experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18. Dependency of leukocyte adhesion and transmigration on the distance of microinjection 
of chemoattractants. Leukocyte adhesion (A) and transmigration (B) were analyzed 60 min after 
microinjection of MIP-1α performed at the distances of 25-50, 75-100, and 175-200 µm from the 
postcapillary venule. Both parameters were evaluated in the ROIs (100x50 µm) along the venule 
opposite the site of microinjection; mean ± SEM; n=3.  
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4.3.3 Tissue distribution of fluorescence dye rhodamine 6G applied via microinjection  
In a next step, we seek to evaluate how chemoattractant is distributed within the cremasteric tissue 
after microinjection. To answer this question, microinjection of the fluorescent dye rhodamine 6G 
was performed and its fluorescence intensity was measured within a time period of 60 min after 
microinjection. Fluorescence intensity was observed in three ROIs (100 x 75 µm): on the vessel 
side ipsilateral to microinjection, on the contralateral side, and 350 µm from the venule (considered 
as background). At baseline conditions prior to microinjection of rhodamine 6G, mean gray values 
on both ipsi- and contralateral side did not differ from background levels (Fig. 19). Immediately 
after microinjection, fluorescence intensity was dramatically increased on the vessel side ipsilateral 
to the microinjection as compared to baseline levels, which remained comparable with the 
background intensity and with that on the contralateral vessel side. Despite a reduction by 
approximately one third already 10 min after microinjection, fluorescence intensity of rhodamine 
6G on the ipsilateral side remained strongly increased as compared to background values as well as 
values detected on the contralateral side (Fig. 19D). Forty minutes after microinjection of 
rhodamine 6G, the fluorescent dye reached the contralateral vessel side as indicated by a slight 
elevation of mean gray values. (Fig. 19D). 
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Fig. 19. A-C: Intravital microscopic images show tissue distribution of rhodamine 6G at 1st min 
(A), 30 min (B), and 60 min after microinjection (C). The fluorescence intensity was determined 
within 60 min; the results are presented in D. Three regions of interests 100 x 75 µm in 
cremasteric interstitial tissue were analyzed: on the side ipsilateral to microinjection, on the 
contralateral side, and in the interstitial tissue 350 µm from the site of microinjection (considered 
as background); n=7.  
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4.3.4 Leukocyte adhesion 
In this part of the study, leukocyte adhesion was observed after microinjections of MIP-1α or PAF. 
In order to compare the character of leukocyte adhesion after microinjection with that induced by 
the conventional route of stimulation, intrascrotal injection of PAF was performed in additional 
group. The numbers of adherent leukocytes were evaluated on both vessel sides (ipsi- and 
contralateral to the microinjection). Leukocyte adhesion was dramatically increased upon 
microinjection of MIP-1α or PAF 60 min after microinjections as compared to microinjection of 
saline (Fig. 21). The extent of leukocyte adhesion did not significantly differ between the groups 
undergoing the microinjection of mediators (Fig. 21A). As a next step, we compared leukocyte 
adhesion on vessel side ipsilateral to the microinjection with that on the contralateral side (Fig. 
21A). Upon microinjection of inflammatory mediators 65-70% of all adherent leukocytes, 
independent of the stimulus applied, were localized on the ipsilateral vessel side (Fig. 20, Fig. 21A 
and B). In contrast, intrascrotal microinjection of PAF was associated with a homogenous 
character of leukocyte adhesion without any preferential localization within the vessel lumen (Fig. 
21A, C). 
 
 
 
 
 
 
 
 
 
Fig. 20. Intravital microscopic images of perivenular microinjection of chemoattractant at the 
moment of injection (magnification 4x) (A) and the same venule 2 min after microinjection with 
adherent leukocytes (shown by arrows) on the ipsilateral to microinjection side of the vessel 
(objective magnification 25x) (B). 
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C
RESULTS   51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21. Leukocyte adhesion. A: Numbers of adherent leukocytes 60 minutes after microinjection of 
saline, MIP-1α, or PAF, and after intrascrotal injection of PAF (PAF i.s.) are presented on the 
vessel side ipsilateral to microinjection in black bars and on the contralateral side in white bars; 
mean ± SEM; *<0.05 vs. saline; n=6; PAF i.s. n=3. B-C: Intravital microscopic images of the 
murine cremaster muscle demonstrate adherent leukocytes (arrows) after microinjection (B) and 
intrascrotal injection of PAF (C); asterisk shows the site of microinjection; objective magnification 
20x; scale bar 25 µm. 
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4.3.5 Leukocyte transmigration 
Emigrated leukocytes were counted in ROIs adjacent to the postcapillary venule on both vessel 
sides. As a result, microinjection of MIP-1α or PAF led to progressive increase in the number of 
emigrated leukocytes, which was significantly increased 60 min after microinjection as compared 
to the microinjection of saline (Fig. 22). No significant differences were detected between all 
groups stimulated with the chemoattractants. Next, the extent of leukocyte transmigration was 
compared on the ipsilateral side with that on the contralateral side of each vessel analyzed (Fig. 
22). As shown in Fig. 22A-B, the majority (more than 70%) of emigrated leukocytes were found 
on the ipsilateral vessel side after microinjection of MIP-1α or PAF as compared to the 
contralateral side. In contrast, no difference was detected between the numbers of emigrated 
leukocytes on both perivascular areas in response to intrascrotal injection of PAF (Fig. 22A, C). 
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Fig. 22. Leukocyte transmigration. A: Numbers of transmigrated leukocytes 60 minutes after 
microinjection of saline, MIP-1α, or PAF, and after intrascrotal injection of PAF (PAF i.s.) are 
presented on the vessel side ipsilateral to microinjection in black bars and on the contralateral 
side in white bars; mean ± SEM; *<0.05 vs. saline; # <0.05 vs. contralateral side; n=6; PAF i.s. 
n=3. B-C: Intravital microscopic images from the murine cremaster muscle demonstrate 
emigrated leukocytes (arrows) after microinjection (B) and intrascrotal injection of PAF (C); 
asterisk show the site of microinjection; objective magnification 20x; scale bar 25 µm.  
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4.3.6 Motility of interstitially migrating leukocytes 
Tracking of emigrated single leukocytes was performed off-line in digitalized intravital 
microscopic time-lapse recordings using the imaging software SimplePCI. Emigrated leukocytes 
were captured in digital video sequences and the parameters of leukocyte interstitial migration, 
such as curve-line and straight-line migration velocity, curve-line and straight-line migration 
distances were determined 60 min upon microinjection of inflammatory mediators. As shown in 
Fig. 23A, B and Fig. 24A-D, microinjection of mediators induced interstitial migration of 
leukocytes. On the ipsilateral side, the interstitial migration was target-oriented toward the sites of 
local inflammation (Fig. 23A, B) and characterized by significantly increased curve-line and 
straight-line migration distances as well as curve-line and straight-line migration velocities as 
compared to emigrated leukocytes in the sham-operated group as well as to leukocytes migrating 
on the contralateral vessel side (Fig. 24A-D). Target-oriented character of interstitial leukocyte 
migration is underlined by the finding that the elevation of straight-line migration distance and 
velocity was several times higher than the increase in curve-line distance and velocity. It is worth 
to be noted that leukocyte motility did not significantly differ between the groups receiving MIP-
1α or PAF in almost all migration parameters, with exception of curve-line migration velocity and 
distance, which were significantly higher upon microinjection of MIP-1α. On the contralateral 
vessel side, however, the differences in the migration parameters between the stimulated group and 
the control group were very weak. In contrary to the stimulation by microinjection of mediators, 
leukocyte migration was rather random during diffuse inflammation upon the PAF intrascrotal 
stimulation (Fig. 23C, D) as shown by significantly lower straight-line migration distance and 
velocity (Fig. 24C, D).  
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Fig. 23. Leukocyte interstitial migration. Interstitially migrating leukocytes were visualized using 
near-infrared RLOT IVM (objective magnification 20x) and tracked in digitalized video recordings 
using imaging software. Green lines on intravital microscopic images and colored lines on the 
panels show the migration tracks of single leukocytes after microinjection of MIP-1α (A and B), 
intrascrotal injection of PAF (C and D), and after microinjection of MIP-1α followed by 
superfusion with the Rho kinase inhibitor Y27632 (E and F); asterisks shows the site of 
microinjection.  
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Fig. 24. Leukocyte motility. Parameters of leukocyte motility such as curve-line migration velocity 
(A) and distance (B), straight-line migration velocity (C) and distance (D) were determined in 
digitalized intravital microscopic video sequences 60 min after microinjection of mediators as well 
as upon intrascrotal application of PAF. Interstitially migrated leukocytes were analyzed during 5 
min using SimplePCI software. Parameters of leukocyte motility on the ipsilateral vessel side are 
presented in black bars, on the contralateral vessel side – in white bars, and after of intrascrotal 
application of PAF – in gray bars; mean ± SEM; *p<0.05  vs. saline, § p<0.05 vs. PAF i.s., & 
p<0.05 vs. PAF, $ p<0.05 vs. contralateral side; n=15.  
 
 
 
4.3.7 Effect of the Rho kinase inhibitor Y27632 on leukocyte motility 
To test our approach, we evaluated the role of Rho kinase for leukocyte interstitial migration in 
vivo. For this, an effect of a Rho kinase inhibitor Y27632 on leukocyte motility was analyzed at 
either 65 min or 90 min after microinjection of MIP-1α. The results presented in Fig. 25 show that 
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5 min of superfusion of the cremaster muscle with Y-27632 reduced the motility of emigrated 
leukocytes by approximately 45% as compared to the control group. In contrast, leukocyte motility 
was almost completely blocked, if exposition of the tissue to the inhibitor was prolonged to 30 min 
(Fig. 23E, F; Fig. 25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25. Effect of Rho kinase inhibition on leukocyte motility. Leukocyte curve-line (A) and 
straight-line velocity (C), curve-line (B) and straight-line distance (D) were analyzed in cremaster 
muscle 60 min after microinjection of MIP-1α (black bars) followed by the superfusion with the 
Rho kinase inhibitor Y27632 (gray bars) for either 5 min or 30 min. In control experiments, the 
cremaster muscle was superfused with saline alone upon microinjection of MIP-1α; mean ± SEM; 
*p<0.05 vs. control; # p<0.05 vs. control at 60-65 min; n=15. 
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4.3.8 Morphological changes and polarization of interstitially migrating leukocytes 
Upon microinjection of PAF, leukocytes moved towards the applied chemoattractant and formed 
ruffles. Then, leukocytes adopted an elongated polarized shape change with a contracted tail and a 
broad front lamellipodia (Fig. 26A). Similar shape changes could be observed in interstitially 
migrating leukocytes moving randomly in animals receiving the chemoattractant via intrascrotal 
injection (Fig. 26B). After application of the Rho kinase inhibitor, interstitially migrating 
leukocytes lost their ability to locomote toward the applied source of chemoattractant (Fig. 26C). 
Thereby, leukocytes became less elongated and more spherical, non polar with single protrusions 
(Fig. 26C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 26. Shape changes in single interstitially migrating leukocytes at different time-points of 
migration tracks. Still images from IVM video recordings obtained 60 min after microinjection of 
PAF (A), 60 min after intrascrotal injection of PAF (B), and 60 min after microinjection of PAF in 
combination with superfusion of Rho kinase inhibitor Y27632 for 30 min (C). A: Directional 
locomotion of leukocyte with protrusions of lamellipodia at the front and tailing uropod after 
microinjection of PAF. B: Polarized leukocyte during random interstitial migration after 
intrascrotal injection of PAF. C: Blocking effect of Rho kinase inhibitor Y27632 on leukocyte 
polarization induced by microinjection of PAF (objective magnification 40x).  
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After microinjection of PAF, leukocytes become strongly polarized with an eccentricity of about 
1.8. (Fig. 27A, D). Although intrascrotal injection of PAF also induced leukocyte polarization, the 
values of cell eccentricity were here significantly less as compared with that after microinjection of 
PAF (Fig. 27B, D). Application of Y27632 abolished the PAF-induced leukocyte polarization and 
the ratio between cell long and short axis was less than 1.2 (Fig. 27C, D). 
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Fig. 27. Polarization of interstitially migrating leukocytes in vivo. Still images from intravital 
microscopic video recordings of interstitially migrating leukocytes obtained at 60 min after 
microinjection of PAF (A), intrascrotal injection of PAF (i.PAF) (B), and microinjection of PAF in 
combination with superfusion of Rho kinase inhibitor Y27632 for 30 min (C) (objective 
magnification 50x). Cell major and minor axes are presented in red and green, respectively. D: 
Quantitative data of the average leukocyte eccentricity after microinjection of PAF, intrascrotal 
injection of PAF, and microinjection of PAF with superfusion of Y27632; mean ± SEM; *p<0.05 
vs. microinjection of PAF, # p<0.05 vs. intrascrotal injection of PAF; n=15.   
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4.3.9 Colocalization of leukocyte migration to the site of microinjection of chemoattractant 
Next, we addressed the question of whether leukocyte really migrate toward the site of 
microinjection. Rhodamine 6G (50-65 Pl; 0.05%) was mixed with MIP-1α and applied via 
microinjection. Leukocyte migration was visualized within the time period from 60 to 80 min after 
microinjection. A switching of near-infrared-RLOT microscopy with fluorescent microscopy 
allowed a simultaneous visualization of migrating leukocytes and tissue distribution of the infused 
chemoattractant.  
As shown in Fig. 28A-C, microinjection was performed in the perivenular regions within 25-50 
µm from the venule. A clear majority of attached and extravasated leukocytes was observed on the 
vessel side ipsilateral to the microinjection (Fig. 28D, F). Single cell tracking revealed that 
interstitially migrating leukocytes moved directly toward the site of application (Fig. 28E). Thus, 
microinjection of MIP-1α induces target-oriented leukocyte adhesion, transendothelial, and 
interstitial migration towards the site of microinjection of chemoattractant. 
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Fig. 28. A-C: Visualization of the application site of MIP-1α with rhodamine 6G at the 1st min 
after microinjection using near-infrared RLOT (A) and fluorescence microscopy (B); C- Merged 
image (objective magnification 10x). D - Directional leukocyte adhesion and emigration visualized 
by RLOT microscopy (asterisk shows microinjection site). E - Interstitially migrating leukocytes 
towards the site of microinjection (shown by asterisk); tracking lines of single leukocytes are 
presented as white arrows (objective magnification 20x). F - Comparison of leukocyte emigration 
on ipsi- vs. contralateral vessel side with prevalence of leukocyte transmigration on the ipsilateral 
side (right side) as compared to the contralateral side (left side) (objective magnification 20x).    
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4.3.10 Visualization of mitochondria redistribution in interstitially migrating leukocytes 
In this part of the study, we combined RLOT and fluorescence microscopy and observed 
redistribution of mitochondria in single interstitially migrating leukocytes upon intrascrotal 
injection of PAF. For imaging of mitochondria, green-fluorescent mitochondrial stain 
MitoTracker® Green was applied systemically. Switching of RLOT and fluorescence microscopy 
allowed simultaneous visualization of mitochondria redistribution in interstitially migrating 
leukocyte accordingly to the changing of cell shape. As shown in the Fig. 29, mitochondria were 
mostly concentrated in the region of the cell corresponding to the uropod in polarizing and 
randomly migrating MitoTracker Green-positive leukocytes.  
 
Fig. 29. Representative intravital microscopic images demonstrate redistribution of mitochondria 
in single interstitially migrating leukocyte during 5 min (objective magnification 63x). The analysis 
was performed 60 min after intrascrotal injection of PAF. Fluorescence microscopic images show 
mitochondria localization and dynamics during random migration of a leukocyte in the interstitial 
tissue; near-infrared RLOT images represent motility and dynamic shape changes of a leukocyte 
during the observed time period. Merged images show colocalization of mitochondria and 
lamellipodia (leading edge) as well as uropod (trailing edge) in the polarized, chaotically 
migrating leukocyte (arrows point to the leading edge).  
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4.3.11 Migration patterns of different leukocyte subsets 
In the final part of the study, we used a combination of RLOT with fluorescence microscopy in 
order to analyze transmigration and interstitial migration of monocytes. For this, microinjection of 
MCP-1 was performed in Cx3CR1gfp/gfp mice, in which blood monocytes express GFP (98). The 
second aim of this experimental set was to compare the migration behavior of GFP-positive 
monocytes with that of neutrophils. As well known, neutrophils comprise more than 85% of the 
leukocyte response to MCP-1 (99). Therefore, we assume that GFP-negative leukocytes 
extravasated after microinjection of MCP-1 in our experiments are neutrophils.  
In our experiments, the number of transmigrated GFP-negative neutrophils and GFP-positive 
monocytes was significantly increased 60 min after microinjection of MCP-1 (Fig. 30) as 
compared to the baseline conditions (data not shown). Transmigration of leukocytes had a 
directional character as shown by the prevalence of the number of extravasated neutrophils and 
monocytes on the vessel side ipsilateral to the microinjection (Fig. 30A). The quantitative analysis 
of leukocyte interstitial migration demonstrated that perivenular microinjection of MCP-1 induces 
a target-oriented migration of neutrophils within the interstitial tissue as shown by increased 
straight-line migration velocity (Fig. 30B) and distance (Fig 30C) as compared to those after 
microinjection of saline (Fig. 24C, D). Straight-line migration velocity of neutrophils was 
comparable between three analyzed time periods (Fig. 30B, C). Monocytes, however, did not 
move toward MCP-1, at least at 60-65 min after microinjection, as indicated by lower levels of 
straight-line migration velocity and directionality (Fig. 30B, C). Interestingly, straight-line velocity 
and distance of monocytes were slightly increased after 70 min and 80 min after microinjection of 
MCP-1 as compared to those after 60 min. (Fig 30B, C). These results suggest a delayed 
chemotactic response of monocytes as compared to neutrophils. Although monocytes displayed a 
target-oriented character of interstitial migration 70 and 80 min after microinjection of MCP-1, 
they migrated slower than neutrophils as presented by lower straight-line migration parameters 
(Fig 7A-D). 
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Fig. 30. A: Representative intravital microscopic images show monocyte and neutrophil 
transmigration 60 min after microinjection of MCP-1 in Cx3CR1gfp/gfp mice (objective 
magnification 20x). Fluorescence intravital microscopic image demonstrates target-oriented 
transmigration of monocytes, RLOT image - target-oriented transmigration of neutrophils; 
merged image - colocalization of extravasated monocytes and leukocytes in the interstitial tissue 
(asterisk shows the site of microinjection; scale bar 20µm). Motility parameters such as straight-
line migration distance (B) and velocity (C) of interstitially migrating neutrophils (black bars) 
and monocytes (gray bars) were analyzed 60, 70, and 80 min after microinjection of MCP-1 in 
Cx3CR1gfp/gfp mice for 5 min, respectively; mean ± SEM; *p<0.05 vs. straight-line migration 
velocity of neutrophils; n=5. 
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5. DISCUSSION 
5.1 Discussion of material and methods 
5.1.1 Animals 
The experiments were performed in mice. The mouse is immunologically well characterized and a 
wide range of specific antibodies is commercially available. Important advantages are also the 
opportunity to use genetically modified animals, the rapid breeding, and low costs for animal care. 
In this study, we used ESAM- and PECAM-1-deficient mice. There are no phenotypic differences 
described for these mouse strains except that ESAM-/- mice have a 10% reduction in weight. 
Absolute and differential leukocyte counts (determined for leukocytes stained for CD4, CD8, 
CD19, Gr-1, and F4-80 antigen) were normal in ESAM-/- mice (51). PECAM-1-/- mice are viable, 
fertile, normal in size and do not display any gross physical or behavioral abnormalities (100). 
Additionally, PECAM-1-/- mice have a normal number of red blood cells, platelets, monocytes 
and lymphocytes but significantly fewer circulating neutrophils than their wild-type counterparts 
(100). Isolated skeletal muscle arterioles from homozygous PECAM-1-/- mice exhibit reduced 
vessel dilation and no significant change in wall shear stress responses when intraluminar flow is 
increased (101). 
 
5.1.2 Experimental model and surgical preparation  
Murine cremaster muscle. Murine cremaster muscle model is widely used in investigations of the 
microcirculation in vivo. This muscle is recognized to be very eligible for studies on leukocyte 
recruitment because of some important specialties, such as the almost two-dimensional vessel 
structure, the “typical” pattern of the expression of endothelial adhesion molecules, and a high 
vessel density. In contrast to parenchymal organs, such as liver or spleen, there is a well-defined 
perivascular space in muscle tissue. This specialty is of particular importance and a prerequisite for 
the analysis of interstitial migration of leukocytes. In addition, there are different application routes 
possible for induction of inflammation in the cremaster muscle, such as a systemic application (e.g. 
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LPS in endotoxemia models), local application of mediators via intramuscular (intrascrotal) 
injection or local superfusion. The anatomically favorable localization of supplying vessels also 
allows the investigation of ischemia-reperfusion injury or even studies on transplantation (102), 
(103), (104). 
Surgical preparation. The preparation of cremaster muscle for IVM was performed according to 
the technique described by Baez with several modifications (93). The preparation technique 
requires some basic microsurgical skills and is routinely unproblematic after a learning phase of 6-
8 weeks. The quality of the surgical preparation was controlled using IVM (low number of 
adherent leukocytes and normal blood flow velocity in non-stimulated mice) and histology (no 
tissue damage in sham-groups). A well-known limitation of the model is the relatively high level 
of leukocyte rolling immediately after surgical preparation.  
Monitoring of experimental animals. In all experiments, the microhemodynamics (centerline blood 
flow velocity), the body temperature, and the white blood cell counts were routinely controlled.  
 
5.1.3 Induction of an inflammatory response 
Inflammatory mediators. In these studies, we used three different mediators: IL-1β, MIP-1α, and 
PAF. IL-1β is produced by various cell types and involved in a variety of cellular activities, 
including cell proliferation, differentiation, and apoptosis. IL-1β acts through two IL-1-receptors: 
IL-1-receptor type 1 and 2. According to classical concept, the IL-1β pathway promotes nuclear 
transcription factor (NF-κB) activation with subsequent synthesis of various inflammatory 
mediators (105). Moreover, IL-1β can directly affect different cells causing the release of other 
proinflammatory mediators such as IL-4, IL-5, IL-8, tumor-necrosis factor (TNF-α), or monocyte 
chemoattractant protein-1 (MCP-1) (106), (107), (108), (109).  
The CC chemokine MIP-1α and the potent phospholipid mediator PAF are both nonspecific 
inflammatory mediators which have been shown to initiate leukocyte recruitment and chemotaxis 
(89), (110), (111), (112), (113). MIP-1α (CCL3) is produced by a variety of cells, including 
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lymphocytes, monocytes/macrophages, mast cells, basophils, epithelial cells, and fibroblasts, and 
binds to CC chemokine receptors-1 and -5 (CCR1 and CCR5) with high affinity to exert its 
biological effects (112). MIP-1α binds to GPCRs CCR1, CCR3, and CCR5, whereas PAF interacts 
with leukocytes via the PAF-receptor, which is also the member of the GPCR-superfamily. 
Activation of GPCRs on leukocytes can lead to the activation of “inside-out” signaling of β2-
integrins with consequent adhesiveness and aggregation (114), priming for enhanced inflammatory 
responses, polarization and directional migration, degranulation, and oxygen radical generation 
(115). Moreover, MIP-1α and PAF can affect leukocyte migration indirectly by stimulating other 
interstitial cells (116), (117). For instance, PAF can activate MAPK and trigger cytokine 
production in fibroblasts (118) as well as stimulate TNF-α production in macrophages (119). Many 
signaling events and subsequent functional responses triggered by the PAF-receptor occur in 
seconds to minutes and do not require new gene expression. 
Application of the inflammatory stimuli. Intrascrotal injection was performed 4 h prior to intravital 
microscopic analysis as described previously (51), (96), (120). For injection, a very fine needle 
was used in an attempt to avoid additional tissue damage. The time period of 4h between the 
injection and intravital microscopy was chosen on the basis of previous work from our laboratory 
(110) as well as from the literature (43), (121), which demonstrated a strong inflammatory 
response 4h after intrascrotal injection. In our own experiments presented in 4.1.2, we observed 
that the extent of leukocyte migration is rather low at 2h after stimulation, at least, if the 
intrascrotal route was chosen.  
One of the major goals of this work was to establish a novel technique for the induction of a local 
inflammatory response as well as target-oriented leukocyte migration – application of micro-
amounts of mediators via controlled microinjection in paravascular regions. The technique is 
discussed in detail in 5.2.3. 
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5.1.4 Intravital microscopy  
Intravital fluorescence microscopy represents the gold standard for the investigation of the 
microcirculation and is widely applied in various organs, such as brain (122), heart (123), lungs 
(124), mesenterium (125), liver (60), small intestine (126) and pancreas (127). Imaging of the 
behavior of already transmigrated leukocytes in the interstitial tissue is, however, limited because 
of difficulties to differentiate leukocytes in the interstitial tissue. The visualization of phase 
gradients within unstained specimens using phase contrast, differential interference contrast or 
Hoffman modulation contrast microscopy enables the study of dynamic cellular events in vitro. 
Recently, our laboratory established a novel method called near-infrared RLOT microscopy which 
combines previously described optical principles with IVM (89). Near-infrared RLOT IVM 
possesses several advantages in comparison to conventional fluorescence microscopy. First, the 
reduction of extinction of hemoglobin and myoglobin by near-infrared light enables high-contrast 
visualization of leukocytes in the interstitial tissue (Fig. 31). Second, low energy transfer on 
cremaster muscle tissue through the usage of the near-infrared light would minimize phototoxicity. 
Third, the division in different phase gradients provides a high tissue penetration of near-infrared 
light in combination with enhanced image quality. In addition, RLOT allows the dynamic 
visualization of leukocyte intravascular recruitment such as leukocyte rolling, adherence, 
transendothelial, and interstitial migration of single leukocytes without the usage of any 
fluorescent dye. However, the resolution of RLOT does not allow the differentiation of various 
leukocyte subpopulations. For phenotyping of transmigrated leukocytes, immunohistochemistry of 
cremasteric tissue samples was performed. 
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Fig. 31. A - Principle of near-infrared RLOT microscopy (description in text). B - Intravital 
microscopic image of cremasteric tissue made using conventional transillumination microscopy 
(objective magnification 20x). Identification of extravasated leukocytes in the interstitial tissue is 
limited because of muscle myoglobin. C- Reduction of myo- and hemoglobin extinction by near-
infrared light during RLOT microscopy allows identifying transmigrated leukocytes as well as 
endothelial structures. 
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5.2 Discussion of the results 
5.2.1 The role of ESAM for IL-1β-induced leukocyte migration in vivo 
ESAM is specifically expressed at endothelial tight junctions and on platelets (54). However, the 
involvement of this adhesion molecule in the regulation of leukocyte migration has been not yet 
investigated. Recent studies demonstrated that ESAM-deficient mice have defects in tumor 
angiogenesis, although embryonic angiogenesis was unaffected (54). Because ESAM localizes at 
endothelial cell junctions and is related to the JAM family (60), which has been discovered as an 
essential regulator of leukocyte diapedesis, we decided to investigate the role of ESAM in 
leukocyte transmigration in the mouse cremaster muscle model using ESAM-disrupted gene mice.  
Local inflammation in the cremaster muscle was induced via intrascrotal injection of IL-1β at 4 h 
prior to intravital microscopic observation. Using near-infrared RLOT microscopy, we analyzed 
leukocyte rolling, adhesion, and transmigration in five randomly chosen postcapillary venules.  
Local application of IL-1β induced leukocyte rolling, adhesion, and transmigration at 4 h after 
application. Although we did not find any significant difference in the number of rolling and 
adherent cells between wild-type and ESAM-/- mice, the number of extravasated leukocytes was 
significantly reduced by almost 50% in ESAM-/- mice as compared to wild-type mice. To rule out 
that the difference in extravasation was caused by differences in leukocyte rolling or adhesion at an 
earlier time point during the 4 h-period of cytokine stimulation, we analyzed leukocyte migration 
at 2 hours after intrascrotal injection of IL-1β. As a result, only few transmigrated leukocytes were 
observed at this time point, whereas leukocyte rolling and adhesion were already well detectable 
and again did not differ between wild-type and ESAM-/- mice. Thus, we conclude that the absence 
of ESAM blocks leukocyte extravasation on the level of transendothelial migration. These data 
provide the first in vivo evidence that ESAM plays a crucial role in leukocyte transmigration and 
are supported by data in a peritonitis model (51) demonstrating that leukocyte extravasation is 
reduced by 70% in ESAM-/- mice. 
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How could ESAM mediate leukocyte transmigration? Can platelet-derived ESAM contribute to 
leukocyte migration? Interestingly, we did not observe platelet recruitment in the murine cremaster 
model upon ischemia-reperfusion in several pilot experiments (data not shown). However, we can 
not exclude that platelet ESAM might mediate leukocyte migration upon stimulation with IL-1β or 
in other organs. With or without platelet ESAM, the endothelial ESAM seems to be predominantly 
relevant in mediating leukocyte transmigration. It has been found that the expression of ESAM 
supports the activation of GTPase Rho (51) and therefore may be involved in signaling 
mechanisms that trigger the opening of endothelial cell contacts (51). In addition, ESAM is 
involved in neutrophil extravasation mechanisms independent of the type of stimulating cytokine 
(TNF-α or IL-1β) (51). This is in contrast to PECAM-1 and ICAM-2 because the disruption of 
their genes in the C57BL/6 mouse strain affects neutrophil extravasation only if IL-1β, but not if 
TNF-α was used for stimulation (128), (129). Phenotyping of emigrated leukocytes after IL-1β 
application in the cremaster muscle and in the peritonitis assay showed that more than 80% of all 
extravasated leukocytes were neutrophils (30). This indicates that ESAM, similar to PECAM-1, is 
a molecule at endothelial cell contacts that selectively affects neutrophil, but not lymphocyte 
extravasation (51). In conclusion, our results suggest ESAM as a new membrane protein at 
endothelial cell junctions that is involved in neutrophil extravasation in vivo. 
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5.2.2 The role of CD99 and CD99L2 for IL-1β-induced leukocyte migration in vivo 
CD99 and CD99L2 are recently identified surface proteins expressed on endothelial cells and 
hematopoetic cells (7), (59). Comparing the functions of CD99 with those of CD99L2 in more 
detail revealed important similarities and striking differences. It has been found that both proteins 
are structurally related with 32% amino acid identity between mouse CD99 and CD99L2 (59). 
They are both type 1 transmembrane proteins with extracellular domains, only slightly larger than 
100 amino acids, rich in O-linked carbohydrates, with no resemblance to any known protein family 
(59). Recently, it has been shown in vitro that antibodies against CD99 blocked the transmigration 
of monocytes through HUVEC monolayers without any inhibitory effect on adhesion (55). 
However, the role of both CD99 and CD99L2 for leukocyte migration in vivo has not yet been 
studied. In this context, cloning of mouse CD99 and CD99L2 antibodies allowed the analysis of 
both proteins in vivo (7). Herein, we analyzed the relevance of CD99 or CD99L2 for IL-1β-
induced leukocyte migration in the mouse cremaster muscle using IVM.  
Our results show that both CD99 and CD99L2 participate in the diapedesis process and are not 
involved in rolling and docking of leukocytes to the vessel wall (130). While this was already 
anticipated for CD99 from in vitro transmigration assays (55), (56), (130) we demonstrate here for 
the first time in vivo that blocking of CD99 or CD99L2 results in a significant reduction of 
leukocyte transendothelial migration, whereas leukocyte rolling and adhesion remain unaffected.  
Since blocking antibodies against CD99 or CD99L2 were applied by intravenous application, we 
were not able differentiate whether it is the leukocyte CD99/CD99L2 or the endothelial 
CD99/CD99L2 that plays a critical role in mediating leukocyte diapedesis. This interesting aspect 
became an object of controversial discussion. On the one hand, it seems unlikely that endothelial 
CD99 and CD99L2 participate in diapedesis by homophilic binding to their respective counterpart 
on neutrophils since CD99L2 was almost undetectable on bone marrow neutrophils and CD99 was 
only weakly expressed (59). The in vitro data, showing that incubating neutrophils with antibodies 
against CD99 and CD99L2 did not reduce transmigration, support this hypothesis. Thus, it seems 
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likely that endothelial CD99 and CD99L2 mediate neutrophil transmigration independent of their 
respective counterparts on the neutrophils (59). On the other hand, however, it can not be excluded 
that CD99 or CD99L2 on peripheral neutrophils are involved in diapedesis, because both proteins 
are expressed at much higher levels on these cells than on bone marrow neutrophils. Moreover, it 
has been reported that binding of antibodies to either neutrophil CD99 or endothelial CD99 
resulted in an equivalent quantitative block of transmigration, suggesting a homophilic interaction 
between CD99 on the endothelial cells or neutrophils (130).  
Recent in vitro study provides evidence about an interdependence of CD99 with PECAM-1 in 
mediation of monocyte migration (55). So, CD99 homophilic interactions between EC and 
neutrophils have been shown to occur downstream of PECAM-1-PECAM-1 interactions (130). An 
analysis by Nomarski optics and confocal microscopic imaging showed that while PECAM-1 
blocked arrest on the EC surface overlying the junctions, CD99 blocked neutrophils that are 
already lodged within the interendothelial junctional space (57). The mechanisms, by which 
CD99-blocked leukocytes become lodged downstream of those blocked by PECAM-1 remains to 
be elucidated. In our study, we analyzed whether CD99 or CD99L2 cooperate with PECAM-1 in 
mediating leukocyte migration in vivo. According to the data in vitro, blocking CD99 alone 
prevents >80% of PMN from transmigrating PMNs; blocking PECAM-1 generally prevents 70-
75% of PMN from transmigrating neutrophils (131). In our experiments, blocking of CD99 and 
CD99L2 in IL-1β-induced local inflammation decreased leukocyte transmigration on 50%; the 
same levels of leukocyte transmigration were found in IL-1β-induced inflammation in cremaster 
muscle in PECAM-1-deficient mice, treated with preimmune IgG (59). We do not know why some 
PMN manage to transmigrate despite the presence of blocking antibodies. We hypothesize that 
PMNs in different stages of their lifespan or different states of activation have a different 
sensitivity to CD99 or PECAM-1. Interesting fact is that blocking both PECAM-1 and CD99 had 
an additive effect, blocking >90% of PMN in vitro (57). In our study, blocking of CD99 and 
CD99L2 with monoclonal antibodies in PECAM-1-deficient mice also showed an additive effect, 
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allowing only 37% of leukocytes to transmigrate through the endothelium. It is possible that some 
functional redundancy exists between PECAM-1 and CD99; however, our data are more suggestive 
of a sequential relationship with CD99 functioning downstream of PECAM-1. Temporal and 
spatial relationship between these molecules and their signaling will be an important area for 
research. Interestingly, a functional relationship between PECAM-1 with JAM-A have been 
investigated recently in vivo in the mouse cremaster model (36). The data from Nourshargh’s 
group showed that dual blockade/deletion of these proteins did not lead to an inhibitory effect 
greater than that seen with blockade/deletion of either molecule alone (36).  
Other molecules are also involved in diapedesis. The existence of PECAM-1 and CD99-
independent pathways is supported by our data as well as by previous studies (59), (130) while 
even with or without blocking antibodies, a small proportion of neutrophils or monocytes are 
capable of transmigration (130).  
In conclusion, our results establish CD99 and CD99L2 as novel endothelial surface proteins that 
participate in leukocyte transmigration into inflamed tissue. 
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5.2.3 Imaging and quantitative analysis of leukocyte directional interstitial migration in vivo 
Leukocyte migration toward the site of inflammation is critical for tissue injury and regeneration. 
Although leukocyte interstitial migration was mostly studied in vitro using two-dimensional 
substrates, the mechanisms triggering interstitial migration of extravasated leukocytes in vivo  
remain poorly investigated. In vitro studies do not take into account leukocyte phenotypic and 
functional changes due to interactions of leukocytes with endothelial cells and basement 
membrane during adhesion and transendothelial migration, which include increased leukocyte 
polarization, phagocytosis, degranulation, release of mediators, and enhanced survival (19). In 
addition, the pro-emigratory action of chemokines on blood leukocytes in vivo is dramatically 
different from their capacity to induce chemotaxis in vitro (65). Although 2D substrates were 
preferentially used for in vitro studies on leukocyte chemotaxis, the mechanisms mediating this 
process seem to be rather different in 2D vs. 3D settings. In contrast to 2D migration, the 3D tissue 
network confines and mechanically anchors cells from all sides so they intercalate alongside and 
perpendicular to tissue structures (136). In this context, recent studies have shown that 2D but not 
3D leukocyte migration seems to be integrin-dependent (136), (77). 
In the present study, we have established a novel approach allowing the in vivo imaging and 
quantitative analysis of directional leukocyte migration and polarization in inflamed tissue. Our 
technique comprises the combination of near-infrared RLOT and multicolor fluorescence IVM in 
the murine cremaster muscle, a microinjection technique for induction of directional leukocyte 
migration, and an imaging program for quantitative analysis of cell motility. 
Microinjection in vivo was applied in several works during the last decade. Using a 
micromanipulator, a very fine tipped pipette can be inserted into a blood vessel or surrounding 
tissue to introduce a variety of substances, pharmaceuticals, peptides, oxygen sensing electrodes 
(138), (139) antibodies as well as cells. Several recent studies applied microinjection in the mouse 
cremaster muscle. So, Constantinescu et al used this technique for continuous injection of reagents 
intravenously (140). Ley et al used the microinjection of chemokine in the murine cremaster 
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muscle for local perivascular application of chemoattractants in studies on mechanisms mediating 
leukocyte rolling and adhesion in vivo (141). In this study, we used perivenular microinjection of 
relevant inflammatory mediators in order to initiate target-oriented leukocyte transendothelial and 
interstitial migration toward the applied stimulus. 
For microinjection, the same concentrations of the mediators were used as applied previously by 
our group and by others to induce an inflammatory response in cremaster muscle via intrascrotal 
injection (89), (110). Although we applied only 4.3x10-8 % of the total dose needed for intrascrotal 
stimulation, this dose was strong enough to locally induce a strong leukocyte recruitment response 
comparable to that after intrascrotal injection. However, microinjection of chemotactic mediators 
did not induce inflammation in remote areas of the cremaster tissue, at least within the time period 
investigated. Inflammatory mediators were injected in tissue at a distance of 25-50 µm from the 
unbranched postcapillary venule, since we observed in previous studies using this model that 
emigrated leukocytes are localized predominantly in tissue areas adjacent 0-25 µm to the venular 
vessels (102). It is worth to be noted that microinjection alone neither induced local inflammation 
nor leukocyte recruitment due to mechanical tissue irritation, as it has been observed in additional 
control experiments (data not shown). Noteworthy, in our pilot experiments we tried to visualize 
migration of single interstitially migrating leukocytes during a longer time period (10-20 min). 
However, it was often difficult to follow a leukocyte for a long time, since it can also move in Z-
axis and can simply disappear into the tissue from the focus unreachable by  IVM.  
At the beginning of the study, we answered the question, how far from the analyzed vessel 
microinjection should be performed. MIP-1α was injected on different distances from the venule: 
25-50 µm, 75-100 µm, and 175-200 µm. As result, we found that a distance of 25-50 µm was 
optimal for inducing chemotaxis, since microinjection on distances 75-100 µm and 175-200 µm 
initiated less leukocyte adhesion and transmigration. Moreover, we evaluated how target-oriented 
leukocyte migration colocalizes with the site of microinjection of chemoattractant. We found that 
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leukocytes adhered, transmigrated and moved in the interstitium predominantly towards the 
microinjection site.  
Next, we evaluated how the applied mediator is distributed in the tissue after microinjection. To 
answer this question, the distribution of the fluorescent dye rhodamine 6G was analyzed after it’s 
microinjection. The results showed a prevalence of fluorescence intensity of rhodamine 6G on the 
ipsilateral side during the analyzed time period of 60 min. However, it is worth to be noted that the 
distribution of the fluorescent dye may be different from the tissue distribution of a 
chemoattractant. Taken together, these results allow us to suggest that, using this setup, we can 
generate a chemotactic gradient in the interstitial tissue with a directional character of leukocyte 
migration. 
Interstitial migration of leukocytes upon stimulation with different mediators. Here, we compared 
the character of leukocyte migration after microinjection of MIP-1α or PAF with that induced 
using a conventional route of stimulation such as intrascrotal injection of PAF. Our results showed 
that microinjection of MIP-1α or PAF initiated a local inflammatory response, which was 
characterized by enhanced leukocyte adhesion, transendothelial migration, and motility of 
interstitially migrating leukocytes. In contrast to the diffuse inflammation upon intrascrotal 
injection of PAF, microinjection of chemoattractants led to leukocyte adhesion and transmigration 
preferentially on the vessel side ipsilateral to the analyzed vessel. This finding indicates that target-
oriented leukocyte recruitment occurs already at the level of intravascular interactions of 
leukocytes with endothelial cells.  
Local injection of the chemoattractants initiated leukocyte interstitial migration as shown by 
significantly increased curve-/straight-line migration distance and velocity as compared to the 
contralateral vessel side as well as to the control group. Whereas the curve-line velocity and 
distance were slightly increased upon mediator microinjection, the effect of local stimulation was 
stronger at the level of straight-line distance and velocity. Indeed, curve-line distance and velocity 
describe the real migration trajectory and characterize general cell motility rather than their 
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movement toward stimuli. Therefore, it is not surprising that the curve-line distance and velocity 
were elevated after intrascrotal injection of PAF, since also a random leukocyte migration would 
increase these parameters. Thus, the common locomotional ability of leukocytes – characterized by 
the curve-line parameters – does not seem to be dependent on the type and route of stimulation. In 
contrast, the elevation of straight-line migration distance that shows how far leukocytes move 
toward the stimuli within the time period analyzed was several times higher than curve-line 
migration parameters after microinjection of chemoattractants as compared to saline 
microinjection. Taken together, these findings demonstrate that local microinjection of relevant 
mediators induces directional leukocyte migration toward the chemotactic stimuli. Comparison of 
the parameters of leukocyte motility between the groups stimulated with MIP-1α and PAF 
revealed, however, a similar response. These data support our previous observations that 
intrascrotal injection or superfusion of these mediators initiates comparable extent of leukocyte 
recruitment and transmigration (89), (110). 
How could microinjection of chemoattractants induce directional leukocyte migration? On the one 
hand, chemoattractants administered via microinjection into a perivascular region of the 
interstitium could diffuse through extracellular matrix and directly activate endothelium on the 
ipsilateral vessel side via G-protein-coupled receptors (GPCRs) on endothelial cells. So called 
“interceptors” such as DARC (Duffy antigen receptor for chemokines) and D6 could transport 
PAF or MIP-1α and present them on the apical side of endothelium (13), (19). Alternatively, the 
endothelium on the ipsilateral side might be stimulated via indirect mechanisms involving the 
release of mediators derived from cells in the interstitium (e.g. myocytes, fibroblasts, mast cells, 
smooth muscle cells). Interestingly, glycosaminoglycans have been shown to bind to chemokines 
and retain them locally in the interstitium, thus creating a chemotactic gradient and preventing 
rapid distribution of the chemokine in the tissue (21), (22).  
Why does intrascrotal injection induce diffuse inflammation in the cremaster muscle? After 
intrascrotal injection, the chemoattractant is homogenously distributed in the whole cremaster 
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muscle and induces an inflammatory response in all venules. This suggestion is supported by the 
fact that we found comparable levels of leukocyte migration in 5-7 vessels from different areas of 
the cremaster tissue after intrascrotal injection of IL-1β or PAF. Thus, absence of a chemotactic 
gradient and uniform presence of the mediator in the cremasteric tissue cause “chemotactic chaos” 
in the interstitium with diffuse character of leukocyte adhesion, transmigration, and random 
motility in the interstitium. 
Role of Rho kinase for polarization and motility of interstitially migrating leukocytes. To prove our 
approach, we addressed the question of whether specific inhibition of Rho kinase would influence 
the motility and polarization of interstitially migrating leukocytes in vivo. Rho kinase, a small 
GTPase, is thought to be the molecular switch to mediate signals to various molecules and 
implicated in the formation of stress fibers and focal adhesions, cell morphology, and smooth 
muscle contraction. Rho kinase acts as the key mediator in cytoskeleton reorganization during 
leukocyte migration by regulating microtubuli disassembly (87), actin polymerization and 
contraction (142), activation and downregulation of β2-integrins in leukocytes (143). In vitro 
studies have shown that Rho kinase is involved in the polarization of T cells (86), the retraction of 
the tail of migrating monocytes (85), neutrophil motility (144), as well as chemoattractant-
mediated actin assembly during neutrophil chemotaxis (145). In our study, inhibition of Rho 
kinase not only attenuated the target-oriented movement and polarization of emigrated leukocytes 
upon microinjection of MIP-1α as shown by significantly reduced straight-line migration 
parameters and eccentricity. In addition, Rho kinase inhibitor also almost completely blocked 
common ability of leukocytes to move in muscle tissue, as shown by marked reduction of curve-
line velocity and distance. Therefore, our study provides in vivo evidence that Rho kinase plays a 
critical role for motility and polarization of emigrated leukocyte toward local chemokine 
stimulation and supports in vitro data from the literature. However, several studies demonstrate 
that Y27632 on monocytes elaborate lamellipodia protrusions, inhibits tail retractions and has no 
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effect on forward movement (85), (146). These controversial data can be explained by stimulus-, 
tissue- and leukocyte subtype-specificity of Rho kinase activity. 
Visualization of mitochondria redistribution in single interstitially migrating leukocytes. In the 
past few years, the generation of transgenic mice expressing GFP or GFP-like molecules under 
cell-specific promoters of multiple fluorescent proteins (147) as well as an application of 
fluorescent antigen-specific antibodies have provided a simultaneous visualization of 
intravascularly recruited leukocyte subsets in living mice (148). Although the assays allowing an 
imaging of intravascular recruitment of different leukocyte subsets were already established in 
vivo, there is no such an approach allowing it regarding leukocyte interstitial migration. Since the 
advantages of RLOT microscopy give an opportunity to visualize dynamics of interstitially 
migrating leukocytes in high quality, we decided to combine RLOT with multicolor fluorescence 
microscopy. First, we visualized the redistribution of mitochondria in single interstitially migrating 
leukocytes during their movement upon intrascrotal injection of PAF. We showed that 
mitochondria were distributed predominantly at the trailing edge of migrating polarized leukocyte 
during a 5 min time period . Recent in vitro studies provide a strong evidence that chemoattractants 
induce the redistribution of mitochondria towards the uropod of polarized migrating leukocytes 
(149), (150). Thus, mitochondrial fission seems to regulate chemoattractant-dependent organelle 
redistribution (150). Mitochondria concentrated at the uropod could provide adenosine 
triphosphate to sustain actomyosin contraction here, thereby enabling retraction of the trailing edge 
and cell advance (150). Based on our pilot experiments, we present here preliminary results, which 
constitute, in the line with the data in vitro, an important advance in our understanding of how 
leukocytes move. However, further investigations are required in order to analyze this 
phenomenon in detail in vivo.  
Migration behavior of neutrophils vs. monocytes. Next, we analyzed migratory patterns of 
neutrophils and monocytes during their directional interstitial migration. Cx3CR1gfp/gfp mice were 
selected as reporters because in the blood all monocytes express GFP (98). Since only few GFP-
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positive cells in the interstitial tissue (which can be tissue macrophages, NK cells, and dendritic 
cells in Cx3CR1gfp/gfp mice (98)) were visualized in ROIs at the baseline, we assumed that almost 
all GFP-positive cells interstitially migrated toward applied MCP-1 were blood monocytes. We 
found that monocytes, despite the ability to locomote directionally toward applied chemoattractant, 
started their target-oriented interstitial migration later as neutrophils and moved rather slowly as 
neutrophils. Interestingly, monocytes have been reported to move slower as neutrophils upon 
stable chemotactic gradient in vitro (151), (152). It seems possible that this capability of 
neutrophils would enable them to accumulate more rapidly at the site of inflammation. Moreover, 
it has been shown that under certain inflammatory conditions, neutrophils produce chemotactic 
factors for monocytes (153), (154), (155). However, the mechanisms of these different locomotive 
patterns of monocytes and neutrophils during inflammatory response should be investigated in 
detail.  
In conclusion, we have validated a novel approach for analysis of leukocyte interstitial migration 
in vivo. In contrast to recently used in vivo chemotaxis assays (91), (137), our technique allows  
not only quantitative analysis of cell motility, but also gives a possibility for in vivo investigation 
of shape changes/polarization and subcellular events in motile immune cells during their 
directional migration. In addition, our assay would enable simultaneous visualization and analysis 
of interstitial migration of different leukocyte subsets during their directed interstitial migration as 
well as their interactions with each other or with apoptotic/necrotic cells in vivo. Local 
administration of bacteria into the interstitium via microinjection technique would permit the 
evaluation of leukocyte chemotaxis towards bacteria as well as bacterial clearance in vivo. This 
approach opens new avenues for in vivo investigations on the mechanisms and spatiotemporal 
dynamics of target-oriented interstitial migration of single leukocytes. 
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6. SUMMARY 
The emigration of leukocytes from the circulation is a critical step during immune surveillance and 
inflammatory reactions that is governed by a coordinated interplay involving a spectrum of 
adhesion and signal molecules. While a great deal has been learned about the early steps of 
leukocyte recruitment, i.e. rolling and adhesion, little is known about the subsequent steps, 
transendothelial and interstitial migration when leukocytes migrate across the endothelial layer 
lining the blood vessel and move to the sites of inflammation. In particular, it is not fully 
understood which endothelial receptors are responsible for extravasation of leukocytes into the 
perivascular space. Moreover, the mechanisms of interstitial migration of leukocytes during 
inflammation remain to be clarified in vivo.  
In the first part of the study, we analyzed the role of ESAM for leukocyte migration in vivo. ESAM 
is a novel adhesion receptor which is specifically expressed at endothelial tight junctions and on 
platelets. Using RLOT intravital microscopy of the murine cremaster muscle, we have shown that 
IL-1β-induced leukocyte transmigration was reduced by about 50% in ESAM-deficient mice 
without affecting leukocyte rolling and adhesion. Our data are supported by findings in the model 
of chemically-induced peritonitis in which the migration of neutrophils was inhibited to a similar 
extent. In summary, ESAM at endothelial tight junctions participates in the migration of 
neutrophils through the vessel wall. 
In the second part of the study, we investigated the role of two other recently discovered receptors, 
CD99 and CDL2, for leukocyte migration. Similar to ESAM, these receptors are expressed at 
endothelial cell contacts but did not belong to any of the known protein families. We demonstrate 
that CD99L2 and CD99 mediate transendothelial migration of neutrophils in vivo without any 
effect on leukocyte rolling and adhesion. Similar findings were also reported in the model of 
chemically-induced peritonitis (59). Finally, we show that the inhibitory effect of anti-CD99 and 
CD99L2 antibodies on cytokine-induced leukocyte transmigration in cremasteric venules is 
amplified in PECAM-1-/- mice. This fact suggests that a functional relationship between PECAM-
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1 and CD99/ CD99L2 might exist in mediating leukocyte transmigration. Taken together, our 
study provides the first evidence for a role of CD99 and CD99L2 in the process of leukocyte 
transendothelial migration in vivo. 
In the third part of the study, we established a novel approach allowing the visualization and 
analysis of directional leukocyte interstitial migration in vivo. Our technique combines RLOT and 
multicolor fluorescence microscopy with microinjection for local application of chemoattractants. 
In the mouse cremaster muscle, we show that microinjection of chemoattractants (MIP-1α and 
PAF) induced directional leukocyte polarization and migration. Combination of RLOT microscopy 
with fluorescence microscopy allowed simultaneous visualization and analysis of migratory 
behavior of different leukocyte subsets upon chemotactic stimulation. Moreover, this approach 
enabled an imaging of subcellular events such as mitochondria redistribution in single polarized 
interstitially migrating leukocytes in vivo. This technique opens new avenues for investigations of 
the mechanisms of interstitial migration of leukocytes as well as the observation of morphological 
changes and subcellular events in different leukocyte subsets during their interstitial migration in 
vivo.
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7. ZUSAMMENFASSUNG 
Die durch ein koordiniertes Zusammenspiel zwischen Adhäsions- und Signalmolekülen 
regulierte Migration von Leukozyten aus den mikrovaskulären Stromgebieten in interstitielle 
Kompartimente stellt einen entscheidenden Schritt in der Pathophysiologie der Immunantwort 
und entzündlicher Reaktionen dar. Während die Mechanismen der initialen, intravaskulären 
Interaktion der Leukozyten mit den Endothelzellen, wie z. B. Rolling und Adhäsion in den 
letzten Jahren weitgehend aufgeklärt wurden, sind die der transendothelialen und interstitiellen 
Migration der Leukozyten zugrundeliegenden Mechanismen noch nicht genügend verstanden. Im 
Besonderen ist nicht vollständig geklärt, welche endothelialen Adhäsionsmoleküle für die 
Extravasation der Leukozyten in den perivaskulären Raum verantwortlich sind. Auch die 
Mechanismen der interstitiellen Migration der Leukozyten werden äußerst kontrovers diskutiert. 
 
Im ersten Teil dieser Studie wurde die Rolle von endothelial cell selective adhesion molecule 
(ESAM) für die Leukozytenmigration in vivo untersucht. ESAM ist ein erst vor kurzem 
entdecktes Mitglied der Immunglobulin-Superfamilie, welches sowohl in Endothelzellkontakten, 
sog. tight-junctions, als auch auf Thrombozyten exprimiert wird. Mittels Reflected Light Oblique 
Transillumination (RLOT)-Mikroskopie am M. cremaster der Maus konnten wir zeigen, dass die 
IL-1β-induzierte Leukozytentransmigration in ESAM-defizienten Mäusen um ca. 50 % reduziert 
war, während Leukozytenrollen und -adhärenz mit den Wildtyp-Tieren vergleichbar waren. 
Diese Ergebnisse legen nahe, dass ESAM den Prozess der Leukozytenauswanderung durch die 
Endothelbarriere vermittelt.  
 
Im zweiten Teil der Arbeit wurde die Rolle von CD99 und CD99L2, zwei ebenfalls erst seit 
einigen Jahren bekannten Adhäsionsrezeptoren, analysiert. Ähnlich wie ESAM werden diese 
Rezeptoren in endothelialen Zellkontakten exprimiert. Unsere Ergebnisse zeigen, dass sowohl 
CD99 als auch CD99L2 die transendotheliale Migration von neutrophilen Granulozyten in vivo 
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mediieren, jedoch keinen Einfluss auf Rolling und Adhäsion haben. Interessanterweise war der 
die Leukozytenmigration hemmende Effekt von gegen CD99 bzw. CD99L2 gerichteten 
Antikörpern bei PECAM-1-defizienten Mäusen deutlich verstärkt, was auf eine kooperative 
Funktion von PECAM- 1 und CD99/CD99L2 bei der Regulation der Leukozytentransmigration 
hinweist. Zusammengefasst liefert diese Studie erste deutliche Hinweise auf eine funktionelle 
Bedeutung von CD99 und CD99L2 bei der transendothelialen Migration der Leukozyten in vivo. 
 
Der dritte Abschnitt der Arbeit beschäftigt sich mit dem In-Vivo-Imaging und den Mechanismen 
der interstitiellen Leukozytenmigration in entzündetem Gewebe. Im Rahmen dieser Studie ist es 
gelungen, eine neue Technik zu etablieren, welche sowohl die intravitale Visualisierung als auch 
die quantitative Analyse der direktionalen interstitiellen Leukozytenmigration in vivo ermöglicht. 
Die Technik basiert auf der Kombination von lokaler Applikation chemotaktischer Substanzen 
mittels kontrollierter Mikroinjektion in das Gewebe mit RLOT- bzw. Fluoreszenz-
Intravitalmikroskopie. Am M. cremaster an der Maus konnte gezeigt werden, dass die 
Applikation des Chemokins MIP-1α (CCL3) sowie des Phospholipids PAF in das interstitielle 
Gewebe eine zielgerichtete Polarisierung und Migration der Leukozyten induziert. Darüber 
hinaus ermöglichte dieses Verfahren das In-vivo-Imaging von subzellulären Ereignissen, wie z.B. 
der Umverteilung von Mitochondrien in polarisierten, interstitiell migrierenden Leukozyten. 
Zusammengefasst erlaubt diese Technik Untersuchungen zu den Mechanismen der interstitiellen 
Leukozytenmigration in vivo sowie die Beobachtung morphologischer Veränderungen und 
subzellulärer Prozesse in interstitiell migrierenden Leukozyten. 
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